

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <p>(51) International Patent Classification<sup>4</sup> :<br/>C07K 3/02, 3/20, 13/00<br/>C07K 15/00, A61K 37/00<br/>C12Q 1/68, C12P 21/00, 21/02<br/>C12N 15/00, 1/20, 1/00<br/>C07H 21/04</p>   | <p>A1</p> | <p>(11) International Publication Number: <b>WO 87/ 06938</b></p> <p>(43) International Publication Date:<br/>19 November 1987 (19.11.87)</p>  |
| <p>(21) International Application Number: PCT/US87/01122</p> <p>(22) International Filing Date: 11 May 1987 (11.05.87)</p> <p>(31) Priority Application Number: 861,529</p> <p>(32) Priority Date: 9 May 1986 (09.05.86)</p> <p>(33) Priority Country: US</p> <p>(71) Applicant: BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. [US/US]; 2450 Bayshore Parkway, Mountain View, CA 94043 (US).</p> <p>(72) Inventor: SCHENK, Dale, B. ; 914 Gwen Drive, Campbell, CA 95008 (US).</p> <p>(74) Agents: BLACKBURN, Robert, P. et al.; Ciotti &amp; Murashige, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).</p> |           | <p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published<br/><i>With international search report.</i></p> |
| <p>(54) Title: ATRIAL NATRIURETIC PEPTIDE RECEPTOR PROTEIN AND ITS ENCODING DNA</p> <p>(57) Abstract</p> <p>Purified native Atrial Natriuretic Peptide (ANP) receptor protein, as well as synthetic ANP receptor and methods of making and using ANP receptor protein and antibodies.</p>  |           |  |

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | FR | France                                   | ML | Mali                     |
| AU | Australia                    | GA | Gabon                                    | MR | Mauritania               |
| BB | Barbados                     | GB | United Kingdom                           | MW | Malawi                   |
| BE | Belgium                      | HU | Hungary                                  | NL | Netherlands              |
| BG | Bulgaria                     | IT | Italy                                    | NO | Norway                   |
| BJ | Benin                        | JP | Japan                                    | RO | Romania                  |
| BR | Brazil                       | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic     | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                        | LI | Liechtenstein                            | SN | Senegal                  |
| CH | Switzerland                  | LK | Sri Lanka                                | SU | Soviet Union             |
| CM | Cameroon                     | LU | Luxembourg                               | TD | Chad                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | TG | Togo                     |
| DK | Denmark                      | MG | Madagascar                               | US | United States of America |
| FI | Finland                      |    |  |    |                          |

-1-

5

ATRIAL NATRIURETIC PEPTIDE  
RECEPTOR PROTEIN AND ITS ENCODING  
DNA

Technical Field

10           The present invention relates to Atrial  
Natriuretic Peptide receptor protein, methods of  
producing both native and synthetic receptor protein,  
and methods of using the receptor protein.

15   Background of the Invention

          Atrial Natriuretic Peptide (ANP) is a potent  
natriuretic and vasorelaxant polypeptide which has been  
isolated from the extracts of mammalian atria. DeBold  
et al., (1981) Life Sci. 28:89-94; Napier et al., (1984)  
20   Ann. Rep. Med. Chem. 19:253-262; Kangawa et al., (1984)  
Biochem. Biophys. Res. Commun. 118:131-139; Flynn et  
al., (1983) Biochem. Biophys. Res. Commun. 117:859-865;  
Napier et al., (1984) Biochem. Biophys. Res. Commun.  
120:981-988; Currie et al., (1984) Science 223:67-69; -  
25   Thibault et al., (1984) FEBS Lett. 167:352-356; Atlas et  
al., (1984) Nature 309:717-719. These peptides have  
been given a variety of names (e.g., atriopeptins and  
cardionatrans), but are now collectively referred to as  
ANP.

30           It has been determined from the sequence of  
cloned cDNA for these peptides that they are all derived  
from the carboxy-terminal region of a precursor protein  
whose structure has been recently established. Yamanaka  
et al., (1984) Nature 309:719-722; Maki et al., (1984)

-2-

Nature 309:722-724; Oikawa et al., (1984) Nature  
309:724-726; Seidman et al., (1984) Science 225:324-  
326; Flynn et al., (1985) Science 228:323-325. The  
5 difference in post-translational processing or  
artifactual degradation during isolation. Several  
synthetic ANPs have also been prepared and shown to  
contain all the biological properties of the native  
peptides. Seidah et al., (1984) Proc. Natl. Acad. Sci.  
10 USA 81:2640-2644; R.P. Nutt et al., in PEPTIDES 1984  
(U. Ragnarsson ed. 1985); Atlas et al., supra.

ANP has been shown to play a significant role  
in blood-pressure homeostasis, regulation of  
extracellular fluid volume, and as an antagonist to the  
15 hypertensive effects of the renin-angiotensin system and  
other hormonal and neurotransmitter systems. ANP has  
been detected in the blood by radioimmunoassay.  
Gutkowska et al., (1984) Biochem. Biophys. Res. Commun.  
125:315-323; Tanaka et al., (1984) Biochem. Biophys.  
20 Res. Commun. 124:663-668. The biological effects of ANP  
are mediated through the binding of ANP to specific  
receptors on cell membranes. The existence of specific  
receptors has been demonstrated in a variety of kidney,  
adrenal cortex, and vascular tissue. Schenk et al. (I),  
25 (1985) J. Biol. Chem. 260:14887-14890; Vandlen et al.,  
(1985) J. Biol. Chem. 260:10889-10892; Misono et al.,  
(1985) Biochem. Biophys. Res. Commun. 130:994-1001;  
Hirose et al., (1985) Biochem. Biophys. Res. Commun.  
130:574-579; Yip et al., (1985) J. Biol. Chem.  
30 260:8229-8232; Schenk et al. (II), (1985) Biochem.  
Biophys. Res. Commun. 127:433-442; Hirata et al., (1985)  
Biochem. Biophys. Res. Commun. 128:538-546; Winkvist et  
al., (1984) Proc. Natl. Acad. Sci. USA 81:7661-7664;  
Napier et al., (1984) Proc. Natl. Acad. Sci. USA

-3-

81:5946-5950; Hirata et al., (1984) Biochem. Biophys. Res. Commun. 125:562-568; De Lean et al., (1984) Endocrinology 115:1636-1638; De Lean et al., (1984) Life Sci. 35:2311-2318.

5           Because of the potent biological activity of ANP, regulation of its levels in the blood would be a therapeutic approach to the treatment of such disorders as hypertension, shock, and the like. To establish therapeutic protocols, however, it is necessary to have  
10 a sensitive assay for determining the levels of ANP in the blood of mammals. Such an assay could also be used to diagnose ailments such as hypertension. ANP receptor protein, if available, could be readily employed in the these assays. While current native and synthetic ANP,  
15 as well as analogs thereof, would allow for the modulation of fluid volume and vascular function by increasing ANP levels, effective therapies may also require ANP levels to be reduced in order to achieve the desired extracellular fluid volume and electrolytic  
20 homeostasis. It is possible that soluble fractions of ANP receptor could be used therapeutically to reduce serum levels of ANP.

          While various attempts have been made to characterize the ANP receptor, it has not been  
25 purified. Furthermore, these attempts at characterization have produced conflicting results. See, e.g., Schenk et al. (I), supra; Vandlen et al., supra; Misono et al., supra; Hirose et al., (1985), supra; Yip et al., supra.

30           Recent work has suggested that there may be more than one ANP receptor. See Leitman et al. (1986) Biochim. Biophys. Acta 885:74-75; Kuno et al. (1986) J. Biol. Chem. 261:5817-5823 (copurification from rat lung of ANP binding and guanylate cyclase activity). Of

-4-

additional interest regarding the ANP receptor are  
Leitman et al. (1986) J. Biol. Chem. 261:11650-11655;  
Scarborough et al. (1986) J. Biol. Chem.  
261:12960-12964; Hayashi et al. (1986) Peptide Chemistry  
5 1985, pp. 27-32; Hirata et al. (1985) Biochem. Biophys.  
Res. Comm. 132:971-984; Napier et al. (1986) Arch.  
Biochem. Biophys. 248:516-522.

It would be highly desirable, therefore, if  
purified ANP receptor protein were available, as well as  
10 genes to facilitate its production through recombinant  
means. Monoclonal antibodies to the receptor protein  
would also be useful, since they could be used to  
characterize the receptor protein, identify additional  
tissue expressing receptor protein, and block ANP  
15 binding to the receptor.

Several receptor molecules unrelated to the ANP  
receptor have been isolated and purified in the prior  
art. Wimalasena et al., (1985) J. Biol. Chem.  
260:10689-10697 (porcine LH/hCG receptor); Petruzzelli  
20 et al., (1984) Proc. Natl. Acad. Sci. USA 81:3327-3331  
(insulin receptor); Schneider et al., (1982) J. Biol.  
Chem. 257:2664-2673 (LDL receptor).

#### Summary of the Invention

25 It is an object of the present invention to  
provide purified ANP receptor protein, both native and  
synthetic.

Another object of the present invention is to  
provide a method of purifying native ANP receptor  
30 protein.

Still another object of the present invention  
is to provide DNA molecules encoding ANP receptor  
protein.

-5-

Yet another object of the present invention is to provide methods of producing ANP receptor protein by recombinant DNA methods.

A further object of the present invention is to  
5 provide antibodies, and cell lines producing such antibodies, which bind an epitope on ANP receptor protein.

These and other objects of the present invention are provided by one or more of the following  
10 embodiments.

In one embodiment, the present invention is directed to a cell-free composition comprising mammalian Atrial Natriuretic Peptide (ANP) receptor protein subunit having a molecular weight of about 60,500  
15 daltons, said receptor protein subunit comprising a minimum of about 75% by weight of the protein in said composition.

In another embodiment, the present invention is directed to proteins having substantial homology to the  
20 60.5 kd ANP receptor subunit and which bind ANP.

In yet another embodiment, the present invention is directed to a method of purifying native ANP receptor protein comprising:

(i) providing a membrane-containing cell  
25 fraction prepared from mammalian cells having ANP receptors;

(ii) solubilizing ANP receptor protein in said membrane fraction with  $C_{12}E_8$  detergent to produce a supernatant containing said ANP receptor protein; and

30 (iii) purifying ANP receptor protein from said supernatant by passing said supernatant through a chromatographic column containing immobilized ANP under conditions whereby said ANP receptor protein is bound to said immobilized ANP, followed by eluting bound ANP

-6-

receptor protein from said column to provide purified ANP receptor protein.

The present invention is also embodied in a method of isolating DNA sequences encoding ANP receptor protein comprising:

- (i) providing a DNA library prepared from a mammalian cell source;
- (ii) screening said DNA library by hybridization with a cDNA or oligonucleotide probe containing codons for an amino acid sequence homologous to a selected region of an ANP receptor protein subunit; and
- (iii) isolating DNA molecules from said DNA library to which said oligonucleotide selectively hybridizes.

Another embodiment of the present invention is a composition comprising a recombinant vector containing a DNA sequence encoding an amino acid sequence homologous to the 60.5 kd ANP receptor protein subunit, said composition being substantially free of recombinant vectors that do not contain said DNA sequence.

Other embodiments of the present invention are directed to cells, such as procaryotic and eucaryotic cells, which are transformed by the above vectors or DNA sequences, as well as methods of producing ANP receptor subunit comprising growing such cells under conditions whereby a peptide comprising ANP receptor protein subunit is expressed and recovered.

A further embodiment of the present invention is directed to anti-ANP receptor protein antibodies substantially free of other antibodies, immortal mammalian cells lines producing such antibodies, and methods of purifying ANP receptor protein with such antibodies.



-7-

Brief Description of the Figures

Figure 1 shows the competitive binding between radiolabeled ANP(4-28) and various ANP peptides to purified ANP receptor protein.

5        Figure 2A shows the N-terminal amino acid sequence determined from purified bovine ANP receptor, and the corresponding synthetic oligonucleotides used to probe cDNA libraries.

10       Figure 2B is a schematic representation of the ANP receptor RNA and the cDNA clones obtained with the probes in Figure 2A.

Figure 3 is the bovine ANP receptor cDNA sequence and the predicted amino acid sequence.

15       Figure 4 is a hydropathicity profile of bovine ANP receptor protein.

Figure 5 is the human ANP receptor cDNA sequence and the predicted amino acid sequence.

Detailed Description of the Invention

20       The present invention provides purified ANP receptor protein in a usable form. Purified ANP receptor protein allows for the amino acid sequence to be determined, nucleic acid probes designed, and ANP receptor genes cloned. See generally Atlas et al., supra; Yamanaka et al., supra; Maki et al., supra; Oikawa et al., supra. Once cloned, the ANP receptor gene can be used to produce synthetic ANP receptor protein. See, e.g. U.S. Patent Nos. 4,440,859; 4,436,815; 4,431,740.

30       The receptor protein (native or synthetic) can be employed, for example, in competitive binding assays to measure the level of ANP in patient sera. ANP receptor protein will also be extremely useful in testing analogs to native ANP for their ability to bind

-8-

or block the ANP receptor. Computer modeling of the ANP receptor binding site may also aid in the design of new compounds which block or bind the ANP receptor site in vivo.

- 5 "Atrial natriuretic peptide receptor protein", or "ANP receptor", refers to a native ANP receptor protein from any mammalian source, including, but not limited to, human, bovine, porcine, equine, ovine, murine, rat, rabbit, hamster, and goat. The term also  
10 includes synthetic ANP receptor protein: i.e., protein produced by recombinant means or direct chemical synthesis. See, e.g., Clark-Lewis et al (1986) Science 231:134-139. ANP receptor protein is a protein found in  
15 the cellular membrane of various vascular and renal tissues, including, but not limited to, kidney cortex cells, vascular endothelial cells, adrenal cortex, adrenal zona glomerulosa, and lung tissue.

- The preferred receptor protein of the present invention is derived from vascular tissue, such as  
20 aortic smooth muscle cells. An illustrative member of the class of vascular ANP receptor proteins is the receptor protein isolated from bovine aortic smooth muscle cells (bovine vascular ANP receptor). ANP receptor protein of this class isolated from other  
25 tissues have the same structure. Bovine vascular ANP receptor protein is comprised of two substantially identical protein subunits. Analysis by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), 10% polyacrylamide concentration, shows that  
30 the dimer has an apparent molecular weight of  $125 \pm 12$  kd (non-reducing conditions) and that the subunit has an apparent molecular weight of  $60.5 \pm 6$  kd (reducing conditions).

To characterize the purified native bovine vascular ANP receptor protein further, its activity as a receptor in vitro was studied. The following ANP peptides, described in Schenk et al. (II), supra, were employed: ANP(4-28), ANP(7-28), and ANP(5-25).  $B_{max}$ ,  $K_i$  and  $K_d$  were calculated by standard methods. See, e.g., Scatchard (1949) Ann. N.Y. Acad. Sci., pp. 600-672. Competitive binding analysis of ANP(4-28) with various ANP peptides is shown in Figure 1. Computer analysis of the binding data shows that the  $B_{max}$  for receptor binding is 5.7 (75% receptor activity) nmol/mg protein with a  $K_d$  equal to 0.3 nM. This corresponds to a stoichiometry of ANP to receptor protein of 1:3/subunit, or 0.7:1/holoreceptor. Purified receptor protein also exhibited an affinity for ANP in the same range as previously recorded for ANP receptor in intact cells: 0.1-10.0 nM. The relative  $K_i$  values for various ANP peptides are as follows: ANP(4-28) 0.3 nM; ANP(7-28) 1.1 nM; and ANP(5-25) 1.12 nM.

20 Native bovine vascular ANP receptor protein was also subjected to amino acid analysis. A partial N-terminal amino acid sequence of the bovine vascular receptor gave the following sequence for amino acids 2-32 of the mature protein:

25.

5                                  10                                  15

X-Ala-Leu-Pro-Pro-Gln-Lys-Ile-Glu-Val-Leu-Val-Leu-Leu-Pro-

20                                  25

Gln-Asp-Asp-Ser-Tyr-Leu-Phe-Ser-Leu-Ala-Arg-Val-Arg-Pro-

30

Ala-Ile-Glu-

One of skill in the art can readily extend the above sequencing to the carboxy terminus of the protein, if desired, by standard protein sequencing methods. A

-10-

simpler method is to clone and sequence the gene for the receptor protein to give the amino acid sequence.

Analysis of the complete cDNA of the bovine receptor in Figure 3 indicates that mature receptor protein is a 496 amino acid polypeptide, expressed as a propeptide. The molecular weight of the putative mature receptor protein is about 56,000, indicating that the native receptor protein may be glycosylated. The human cDNA (Figure 5) shows a similar structure.

10 The prosequence of bovine vascular ANP receptor suggests that 41 amino acids are removed from the N-terminus of the receptor precursor during maturation. The first N-terminal 21 amino acids define an extremely hydrophobic potential membrane translocation signal. 15 Walter et al. (1984) Cell 38:5-8. By the consensus rules of Von Heijne, (1983) Em. J. Biochem. 133:17-21, two highly probable sites for cleavage by signal peptidase occur in the predicted sequence, one after residue 18 and the other after residue 31. The 20 remaining 10 to 23 residues between these sites and the mature N-terminus (Glu<sup>42</sup>) suggest that subsequent proteolytic precessing of the receptor occurs either during transport to the membrane or after deposition. In this regard it is worth noting that the sequence 25 preceding Glu<sup>42</sup> (residues 22-41) is hydrophilic and ends in a hexapeptide containing four arginines. Three potential carbohydrate addition sites are present: Asn 82, 289, and 465. The presence of Cys<sup>496</sup> so close to the transmembrane domain indicates that it is a likely 30 site for the disulfide linkage of the homodimer.

The bovine vascular ANP receptor precursor contains several regions of significant hydrophobic character which are obvious from the hydropathicity plot of Figure 4. At most, six hydrophobic regions of

-11-

greater than 20 amino acids can be found, and the first of these (AA 1-21) is probably a signal peptide. One other extremely hydrophobic region (478-500) occurs adjacent to two very hydrophilic regions and is a likely candidate for a transmembrane domain. The region C-terminal to this domain begins with the sequence Arg-Lys-Lys-Tyr-Arg, which is an excellent potential membrane anchor. The ANP receptor is an acidic molecule with most of its negative charge outside the cell, possibly reflecting the fact that its ligand is a basic protein.

Further analysis of the content of particular amino acid residues in the native bovine receptor gave the results shown in Table I, where the results are expressed as number of amino acid residues ( $\pm 20\%$ ) per 500 residues (estimate of 500 residues per 60 kd subunit).

20

25

30

-12-

Table I

|    | <u>Amino Acid</u>         | <u>No. of Residues*</u> |        |
|----|---------------------------|-------------------------|--------|
|    | Aspartic Acid (Asp + Asn) | 27.0                    | 14.0** |
| 5  | Glutamic Acid (Glu + Gln) | 21.3                    | 36.8   |
|    | Serine (Ser)              | 32.1                    | 37.4   |
|    | Glycine (Gly)             | 47.5                    | 47.2   |
|    | Histidine (His)           | 10.3                    | 13.2   |
|    | Arginine (Arg)            | 38.7                    | 35.1   |
| 10 | Threonine (Thr)           | 26.2                    | 24.4   |
|    | Alanine (Ala)             | 51.0                    | 48.0   |
|    | Proline (Pro)             | 25.2                    | 22.1   |
|    | Tyrosine (Tyr)            | 21.0                    | 25.0   |
|    | Valine (Val)              | 37.7                    | 37.4   |
| 15 | Methionine (Met)          | 8.6                     | 6.6    |
|    | Isoleucine (Ile)          | 32.5                    | 27.2   |
|    | Leucine (Leu)             | 48.7                    | 54.6   |
|    | Phenylalanine (Phe)       | 25.0                    | 30.0   |
|    | Lysine (Lys)              | 34.6                    | 36.2   |
| 20 | Cysteine (Cys)            | 2.0                     | 4.6    |

\*Est. of residues (+20%) in bovine vascular ANP receptor protein subunit per 500 residues.

\*\*As before, but protein reduced and alkylated.

25        The amino acid composition of the purified  
 receptor indicates that it contains 4.6 cysteine  
 residues per 500 amino acids, which is in good agreement  
 with the 5 predicted to be present in the mature  
 receptor. The odd number of cysteines would appear to  
 30        reflect the intermolecular disulfide bonds which hold  
 receptor subunits together.

The above data indicate that the two subunits  
 making up the native receptor are either identical or  
 substantially identical (i.e., 90%-95% homologous). It

-13-

is most likely that they are identical, which can be determined by further sequencing of the native peptide, cDNA or genomic clones.

The above data indicate that the ANP receptor described herein is a homodimer, the native subunit having a molecular weight of approximately 60,500, while the nonglycosylated subunit has a molecular weight of approximately 56,000. Some evidence indicates that there may also be native ANP binding proteins having molecular weights of approximately 120,000 and 70,000, and that there may be different functions for each of these proteins. For example, the 120 kd polypeptide observed under fully reducing conditions most closely correlates with guanylate cyclase activity. Unlike the 60.5 kd polypeptide described herein, it does not bind well to truncated ANP analogs. This suggests that the 120 kd receptor may be responsible for stimulating guanylate cyclase activity, while the 60.5 kd receptor has an alternative mode of action; e.g., a clearance receptor. Applicants, however, do not wish to be bound by this hypothesis. Despite the difference in molecular weight and activity, it may be that all of the observed species of ANP receptor protein are encoded by the same gene or a family of substantially similar genes, and the observed differences could result from different post-transcriptional or post-translational processing.

The amino acid sequence of mammalian 60.5 kd vascular ANP receptor protein subunit is highly conserved among mammalian species and different tissues. For example, the bovine and human sequences are at least about 95-97% homologous, the human sequence being determined from kidney and placental cDNA. In general, native ANP receptor protein subunit (or the binding regions of related proteins) isolated from other

-14-

species and/or tissues will have at least about 75% amino acid homology to bovine or human vascular ANP receptor protein subunit, and generally at least about 85% homology. In some cases, homology may be about 90% to about 95% or higher. Other native ANP receptor proteins will be comprised, therefore, of homologous protein subunits. These other solubilized ANP receptor proteins can be further characterized by their ability to bind ANP peptides with high affinity. For example, ANP(4-28) will have a  $K_i$  value of  $\leq 10$ -20 nM, and preferably  $\leq 5$  nM. It is particularly preferred that the ANP receptor protein have a relative  $K_i$  value of  $\leq 1$  nM for ANP(4-28).

Synthetic ANP receptor may also be slightly different from bovine or human vascular ANP receptor in amino acid composition. It is often expedient, for example, to change or delete amino acid residues in nonessential regions (*i.e.*, that do not eliminate receptor function) when engineering an expression vector. It may also be desirable to deliberately alter the amino acid sequence to change the binding affinity to ANP. In general, the affinity ( $K_i$ ) of synthetic receptor should be  $\leq 10$  nM for ANP(4-28). The amino acid sequence homology of synthetic receptor to bovine or human vascular ANP receptor will generally be in the range described above for native ANP receptors, at least for those regions that are not deleted or changed (*e.g.*, as in a fusion protein).

Purification of ANP receptor protein from cells comprises three basic steps: preparation of the cells, solubilization of ANP receptor in an active and stable form, and purification of the receptor by affinity chromatography. A preferred cell source is bovine aortic smooth muscle cells, since they contain about



-15-

250,000 ANP receptor sites per cell. Cultured cells have the additional benefit of being relatively protease-free compared to most tissue sources. This facilitates stabilization and purification of active  
5 receptor protein. Other cell lines, such as the rat smooth muscle embryonic thoracic aortic cell line A10 (ATCC CRL-1476) are known in the art.

The preferred cell line is established from explants of bovine aorta, as described by Longenecker  
10 et al., (1982) J. Cell Physiol. 113:197-202. The smooth muscle cell line can be grown in roller bottles by standard procedures and harvested when sufficient cell mass is obtained. Harvested cells are pelleted by centrifugation and then homogenized, for example, by  
15 grinding with a mortar and pestle. Receptor protein is then solubilized from this homogenized cell fraction with the detergent C<sub>12</sub>E<sub>8</sub> (octaethyleneglycol dodecyl ether); available from Calbiochem-Behring (San Diego, CA). Numerous detergents were tried as a substitute for  
20 C<sub>12</sub>E<sub>8</sub>. None of the other detergents, however, solubilized the receptor protein without substantially reducing ANP receptor activity.

Solubilized ANP receptor is purified by affinity chromatography. Various methods of  
25 purification by affinity chromatography are known to those skilled in the art. See generally Cooper in TOOLS OF BIOCHEMISTRY, pp. 234-254 (John Wiley & Sons, 1977). The general approach for the purification of ANP  
30 receptor protein is: (1) passing the solubilized receptor fraction through a column to which an ANP peptide has been bound, (2) washing the column under dissociating conditions where the receptor remains bound to the ANP peptide, (3) dissociating the receptor/ANP complex, and (4) removing excess ligand and restoring binding activity of the receptor.

-16-

The above procedure provides a purified, cell-free composition wherein vascular ANP receptor protein comprises at least about 75-80% of the protein fraction of the composition. Preferably, chromatography conditions are selected so that the protein fraction of the composition comprises at least about 90% ANP receptor protein, and optimally at least about 98% receptor protein. By selection of cell source, various ANP receptor proteins, such as bovine or human, can be prepared. See generally ANIMAL CELL CULTURE (R.I. Freshney ed. 1986).

Once purified receptor protein is obtained, it can be readily sequenced by any of the various methods known to those skilled in the art. For example, the amino acid sequence of the receptor protein can be determined from the purified protein by repetitive cycles of Edman degradation, followed by amino analysis by HPLC. Other methods of amino acid sequencing are also known in the art.

Once the amino acid sequence is determined, oligonucleotide probes which contain the codons for a portion of the determined amino acid sequence are prepared and used to screen DNA libraries for genes encoding the receptor protein. The basic strategies for preparing oligonucleotide probes and DNA libraries, as well as their screening by nucleic acid hybridization, are well known to those of ordinary skill in the art. See, e.g., DNA CLONING: VOLUME I (D.M. Glover ed. 1985); NUCLEIC ACID HYBRIDIZATION (B.D. Hames and S.J. Higgins eds. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gate ed. 1984); T. Maniatis, E.F. Fritsch & J. Sambrook, MOLECULAR CLONING: A LABORATORY MANUAL (1982).

First, a DNA library is prepared. The library can consist of a genomic DNA library from a selected

-17-

mammal, such as a human. Human genomic libraries are known in the art. See, e.g., Lawn et al., (1978) Cell 15:1157-1174. DNA libraries can also be constructed of cDNA prepared from a poly-A RNA (mRNA) fraction by

5 reverse transcription. See, e.g., U.S. Patent Nos. 4,446,235; 4,440,859; 4,433,140; 4,431,740; 4,370,417; 4,363,877. The mRNA is isolated from a cell line or tissue known to express the receptor protein. Cell

10 lines or tissue expressing ANP receptor protein are known in the art. cDNA (or genomic DNA) is cloned into a vector suitable for construction of a library. A preferred vector is a bacteriophage vector, such as phage  $\lambda$ . The construction of an appropriate library is within the skill of the art.

15 Once the library is constructed, oligonucleotides to probe the library are prepared and used to isolate the desired ANP receptor protein gene. The oligonucleotides are synthesized by any appropriate method. The particular nucleotide sequences selected

20 are chosen so as to correspond to the codons encoding a known amino acid sequence from the receptor protein. Since the genetic code is redundant, it will often be necessary to synthesize several oligonucleotides to cover all, or a reasonable number, of the possible

25 nucleotide sequences which encode a particular region of the protein. Thus, it is generally preferred in selecting a region upon which to base the probes, that the region not contain amino acids whose codons are highly degenerate. It may not be necessary, however,

30 to prepare probes containing codons that are rare in the mammal from which the library was prepared. In certain circumstances, one of skill in the art may find it desirable to prepare probes that are fairly long, and/or encompass regions of the amino acid sequence which would

-18-

have a high degree of redundancy in corresponding nucleic acid sequences, particularly if this lengthy and/or redundant region is highly characteristic of the receptor protein. Probes covering the complete gene, or  
5 a substantial part of the genome, may also be appropriate, depending upon the expected degree of homology. Such would be the case, for example, if a cDNA of bovine vascular ANP receptor was used to screen a human gene library for human ANP receptor protein. It  
10 may also be desirable to use two probes (or sets of probes), each to different regions of the gene, in a single hybridization experiment. Automated oligonucleotide synthesis has made the preparation of large families of probes relatively straightforward.  
15 While the exact length of the probe employed is not critical, generally it is recognized in the art that probes from about 14 to about 20 base pairs are usually effective. Longer probes of about 25 to about 60 base pairs are also used.

20 The selected oligonucleotide probes are labeled with a marker, such as a radionucleotide or biotin using standard procedures. The labeled set of probes is then used in the screening step, which consists of allowing the single-stranded probe to hybridize to isolated ssDNA  
25 from the library, according to standard techniques. Either stringent or permissive hybridization conditions could be appropriate, depending upon several factors, such as the length of the probe and whether the probe is derived from the same species as the library, or an  
30 evolutionarily close or distant species. The selection of the appropriate conditions is within the skill of the art. See generally, NUCLEIC ACID HYBRIDIZATION, supra. The basic requirement is that hybridization conditions be of sufficient stringency so that selective

-19-

hybridization occurs: i.e., hybridization is due to a sufficient degree of nucleic acid homology (e.g., at least about 70-75%), as opposed to nonspecific binding. Once a clone from the screened library has been identified by positive hybridization, it can be confirmed by restriction enzyme analysis and DNA sequencing that the particular library insert contains a gene for the receptor protein.

Alternatively, a DNA coding sequence for ANP receptor subunit can be prepared synthetically from overlapping oligonucleotides whose sequence contains codons for the amino acid sequence of ANP receptor protein subunit. Such oligonucleotides are prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, (1981) Nature 292:756; Nambair et al., (1984) Science 223:1299; Jay et al., (1984) J. Biol. Chem. 259:6311.

A DNA molecule containing the coding sequence for ANP receptor protein subunit can be cloned in any suitable vector and thereby maintained in a composition substantially free of vectors that do not contain the coding sequence of the ANP receptor gene (e.g., other library clones). Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of recombinant DNA vectors for cloning and the host cells which they transform include bacteriophage  $\lambda$  (E. coli), pBR322 (E. coli), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFR1 (gram-negative bacteria), pME290 (non-E. coli gram-negative bacteria), pHV14 (E. coli and Bacillus subtilis), pBD9 (Bacillus), pIJ61 (Streptomyces), pUC6 (Streptomyces), actinophage  $\phi$ C31 (Streptomyces), YIp5 (yeast), YCp19 (yeast), and bovine

-20-

papilloma virus (mammalian cells). See generally, DNA CLONING: VOLUMES I & II, supra; MOLECULAR CLONING: A LABORATORY MANUAL, supra.

In one embodiment of the present invention, the coding sequence from an ANP receptor protein gene is placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control sequences"), so that the DNA sequence encoding the receptor protein (referred to herein as the "coding" sequence) is transcribed into RNA in the host cell transformed by the vector. The coding sequence may or may not contain a signal peptide or leader sequence. The coding sequence may also contain either the sequence for pro ANP receptor, or for mature ANP receptor. In bacteria, mature receptor protein subunit is preferably produced by the expression of a coding sequence which does not have any signal peptide, or by expression of a coding sequence containing the leader sequence in a system when post-translational processing removes the leader sequence. The determination of the point at which the mature protein begins and the signal peptide ends is easily determined from the N-terminal amino acid sequence of the mature protein (Figure 2). The receptor protein can also be expressed in the form of a fusion protein, wherein a heterologous amino acid sequence is expressed at the N-terminal. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437.

The recombinant vector is constructed so that the receptor protein coding sequence is located in the vector with the appropriate control sequences, the positioning and orientation of the receptor coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the

-21-

control of the control sequences (i.e., by RNA polymerase which attaches to the DNA molecule at the control sequences). The control sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequence and an appropriate restriction site downstream from control sequences. For expression of the receptor protein coding sequence in procaryotes and yeast, the control sequences will be heterologous to the coding sequence. If the host cell is a procaryote, it is also necessary that the coding sequence be free of introns; e.g., cDNA. If the selected host cell is a mammalian cell, the control sequences can be heterologous or homologous to the receptor protein coding sequence, and the coding sequence can be genomic DNA containing introns or cDNA. Either genomic or cDNA coding sequence may be expressed in yeast.

A number of procaryotic expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,440,859; 4,436,815; 4,431,740; 4,431,739; 4,428,941; 4,425,437; 4,418,149; 4,411,994; 4,366,246; 4,342,832. See also British Patent Specifications GB 2,121,054; GB 2,008,123; GB 2,007,675; and European Patent Specification 103,395. Preferred expression vectors, however, are those for use in eucaryotic systems. See, e.g., commonly owned U.S.S.N. 809,163, filed 16 December 1985, the disclosure of which is incorporated herein. Yeast expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,446,235; 4,443,539; 4,430,428. See also European Patent Specifications 103,409; 100,561; 96,491. Another preferred expression system is

-22-

vector pHS1, which transforms the Chinese hamster ovary cells. The use of the vector is described in the commonly owned application U.S.S.N. 804,692, filed 4 December 1985, the disclosure of which is incorporated  
5 herein.

Recombinant ANP receptor protein subunit can be produced by growing host cells transformed by the expression vector described above under conditions whereby the ANP receptor protein is produced. ANP  
10 receptor protein is then isolated from the host cells and purified. If the expression system secretes ANP receptor protein into growth media, the receptor protein can be purified directly from cell-free media. To  
15 obtain secretion, it will generally be necessary to delete the codons for the membrane binding portion of the receptor. If the receptor protein is not secreted, it is isolated from cell lysates. The selection of the appropriate growth conditions and recovery methods are  
20 within the skill of the art.

Either native or synthetic ANP receptor protein  
20 can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, purified receptor protein is used to immunize a selected  
mammal (e.g., mouse, rabbit, goat, horse, etc.) and  
25 serum from the immunized animal later collected and treated according to known procedures. Compositions containing polyclonal antibodies to a variety of antigens in addition to the receptor protein can be made  
substantially free of antibodies which are not anti-ANP  
30 receptor protein antibodies by passing the composition through a column to which ANP receptor has been bound. After washing, polyclonal antibodies to ANP receptor are eluted from the column. Monoclonal anti-ANP receptor protein antibodies can also be readily produced by one



-23-

skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known.

Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct

5 transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., HYBRIDOMA TECHNIQUES (1980); Hammerling et al., MONOCLONAL ANTIBODIES AND T-CELL HYBRIDOMAS (1981); Kennett et al., MONOCLONAL ANTIBODIES (1980).

10 By employing ANP receptor protein (native or synthetic) as an antigen in the immunization of the source of the B-cells immortalized for the production of monoclonal antibodies, a panel of monoclonal antibodies recognizing epitopes at different sites on the receptor  
15 protein molecule can be obtained. Antibodies which recognize an epitope in the binding region of the receptor protein can be readily identified in competition assays between antibodies and ANPs. Such antibodies could have therapeutic potential if they are  
20 able to block the binding of ANP to its receptor in vivo without stimulating the physiological response associated with ANP peptide binding. Antibodies which recognize a site on the receptor protein are also  
25 useful, for example, in the purification of ANP receptor protein from cell lysates or fermentation media, and in characterization of the receptor protein. In general, as is known in the art, the anti-ANP receptor antibody is fixed (immobilized) to a solid support, such as a column or latex beads, contacted with a solution  
30 containing the receptor protein, and separated from the solution. The receptor protein, bound to the immobilized antibodies, is then eluted.

The following examples are presented for illustrative purposes only and are not intended to limit the scope of the invention in any way.

-24-

Example I

This example is directed to the purification of ANP receptor protein from vascular tissue and its physical characterization.

- 5           The bovine aortic smooth muscle (BASM) cell line was originally established by Longenecker et al. and is described at (1982) J. Cell Physiol. 113:197-202. A bovine aortic smooth muscle cell line established according to this method and named Q-2 has  
10       been deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, USA under the accession number CRL-9088. After initial growth in tissue culture and subsequent cloning, stockpiles of cells were frozen in liquid nitrogen.
- 15       Cells used for purification of the ANP receptor protein were obtained after 4-15 passages of the cells. The cells were grown under standard conditions in 15% bovine serum and Dulbecco's Modified Eagle's medium in 100  
20       roller bottles (850 cm<sup>2</sup> each). Cells were harvested from the roller bottles by twice rinsing with 50 ml of phosphate-buffered saline (PBS) containing 5 mM EDTA. The same buffer containing 10 µg/ml elastase and 25  
25       µg/ml collagenase was then added to each roller bottle. After an 8-10 min incubation with constant rolling, released cells were pooled, placed on ice, and bovine serum added to 5% (v/v). The cells were  
30       centrifuged at 5,000 x g for 10 min at 4°C. The pellet was resuspended in 250 ml of PBS/EDTA and centrifuged in the same manner. This pellet was again resuspended in 30 ml of homogenization buffer (50 mM Tris HCl, pH 7.5; 5 mM EDTA; 100 mM NaCl; 0.25 M sucrose; 0.1 mM phenyl methyl sulfonyl fluoride; 25 µg/ml aprotinin; 25  
µg/ml leupeptin) at 4°C.

-25-

The cells were homogenized with a ground glass pestle using 10 strokes on ice. The homogenized cells were centrifuged at 100,000 x g for 30 min at 4°C. The pellet was resuspended in homogenization buffer and re-homogenized as described above. This material was again centrifuged at 100,000 x g for 30 min at 4°C. The final pellet was resuspended in 10 ml of homogenization buffer, and protein content was determined by the method of Bradford. (1976) Anal. Biochem. 72:248-251. The membranes were adjusted to 5 mg protein/ml by the addition of homogenization buffer. Receptor binding activity in this fraction was detected with <sup>125</sup>I-ANP(2-28) as described in Schenk et al., (1985) Biochem. Biophys. Res. Commun. 127:433-442. The concentration-dependent binding exhibited by this fraction suggested that 80% of the cell surface receptor activity remained at this stage of the purification.

The membrane fraction exhibiting ANP receptor activity was diluted in an equal volume of PBS/EDTA, followed by the slow addition over a 10-min period of a solution containing C<sub>12</sub>E<sub>8</sub> detergent (20 mg/ml) until a final C<sub>12</sub>E<sub>8</sub> concentration of 4 mg/ml was obtained. This solution was then centrifuged at 100,000 x g for 1 hr at 4°C and the supernatant retained. Binding studies, as described above, showed that 65% of the total ANP binding sites in the membranes were solubilized by this procedure. The solubilized ANP receptor from this preparation was extremely stable, and no change in binding activity was detected after storage of two weeks at 4°C, or three months at -20°C.

An affinity matrix was made by coupling 40 mg human ANP(4-28) to 4 ml of Affi-gel 10 (Bio-Rad) as described by the manufacturer. Solubilized ANP receptor was adjusted to 10 mM CaCl<sub>2</sub> and MgCl<sub>2</sub> and filtered

-26-

through 0.2  $\mu$ m filters (type GE, Millipore). The filtrate was chromatographed on the ANP-agarose column at a flow rate of 0.5 ml/min at 21°C. The column was washed with binding buffer (100 mM Tris HCl, pH 7.50; 100 mM NaCl; 4 mg/ml  $C_{12}E_8$ ; 10 mM  $CaCl_2$ ; and 10 mM  $MgCl_2$ ) until the effluent reached  $A_{280} = 0.000$ . Then 6.0 ml of elution buffer (10 mM Na acetate, pH 5.00; 100 mM NaCl; 4 mg/ml  $C_{12}E_8$ ; 10 mM  $CaCl_2$ ; 10 mM  $MgCl_2$ ) was added and the eluent was placed on ice and immediately adjusted to 37% (v/v) acetone. The solution was centrifuged at 4,000 x g for 10 min at 4°C and thoroughly aspirated. The pellet was resuspended in 3.0 ml of binding buffer and analyzed for purity, receptor binding activity, and amino acid sequence.

Analysis by SDS-PAGE (10% polyacrylamide concentration) under reducing and non-reducing conditions was conducted. Under non-reducing conditions, a single protein band at 125 kd was seen. Treatment of the purified receptor with 10 mM dithiothreitol, a reagent that reduces cystine residues to cysteines, resulted in the appearance of a single protein band at 60.5 kd. This data demonstrates that the ANP receptor protein is essentially pure, and that the active receptor from aortic smooth muscle cells is a dimer of two identical subunits attached by disulfide bridges.

Competitive binding of  $^{125}I$ -ANP(4-28) against various ANP peptides to the purified receptor is shown in Figure 1. The tested ANP peptide included hANP(4-28), hANP(7-28) and atriopeptin I. Gamma-melanocyte stimulating hormone ( $\gamma$ -MSH) was employed as a negative control. Computer analysis (program RS-1; Bolt, Beranek & Newman, Boston, MA) of the binding data showed that the  $B_{max}$  for the receptor

-27-

binding is 5.7 nmol/mg protein with a  $K_d = 0.3$  nM. This corresponds to a stoichiometry of ANP to receptor protein of 1:3 kd subunit, or 0.7:1.0/holoreceptor.

Additional studies were conducted with ANP peptides. The relative  $K_i$  values of 0.3 nM for ANP(4-28), 1.1 nM for ANP(7-28), and 1.12 nM for ANP(5-25) are in agreement with data reported previously for cell surface receptors.

Twenty-five  $\mu$ g of the purified ANP receptor was subjected to repetitive cycles of Edman degradation, followed by amino acid analysis using HPLC on a Applied Biosystems 470A gas-phase sequenator. Analysis revealed only a single sequence of amino acids. This sequence, and corresponding nucleotide sequences, are shown in Figure 2A.

#### Example II

This example is directed to a protocol for obtaining full-length coding sequences of the bovine ANP receptor.

Probes were designed based on the N-terminal sequence of ANP receptor deduced in Example I. The sequences are shown in Figure 2A. Oligonucleotide sequences are presented 3' to 5'. Probes were (1) a 24-fold degenerate 14-mer probe, (2) a 48-fold degenerate 14-mer probe, and (3) a 51-mer probe designed using bovine preferred codon choices. Four different versions of probe 3 were prepared in case the AGA/G codon was used for serine instead of the TCX codon, and in case CpG, a dinucleotide under-represented in eukaryote genomes, was not present in the receptor mRNA. Accordingly, boxed nucleotides indicate that either A was present in both positions or G was present in both positions. Asterisks indicate mismatches in the

-28-

51-mer probe versus the receptor cDNA sequences obtained (see Figure 2A). Hybridization probes were synthesized (Applied Biosystems model 380a), purified by gel electrophoresis, and radiolabeled with [ $\gamma^{32}$ P]ATP and T4 polynucleotide kinase.

A cDNA was prepared from BASM cells as follows. Membrane associated polysomes were purified from BASM cells essentially as described [Sebbain, R. et al. (1983) J. Biol. Chem. 258:3294-3303] and double-strand cDNA was synthesized by the method of Land et al. (1981) Nucleic Acids Res. 9:2251-2266. cDNAs fractionated on Sephacryl S400 (Pharmacia) were ligated to EcoRI adapters and cloned in  $\lambda$ gt10 [Wood, et al. (1984) Nature 312:330-333]. A library of app.  $9 \times 10^6$  recombinant phage was obtained. Plaque lifts were screened by hybridization with combined 51-mer probes in 20% formamide plus 6X SSC (0.9 M NaCl, 0.09 M sodium citrate), 10% dextran sulfate, 0.1% SDS, 5X Denhardt's (0.1% each of bovine serum albumin, polyvinyl pyrrolidone, and Ficoll), and 100  $\mu$ g/ml yeast ribosomal RNA at an initial temperature of 55°C, dropping to 40°C overnight. Clones corresponding to positive hybridization signals were confirmed by hybridization to probes 1 and 2 and plaque purified. Two clones (pANPRc-1 and pANPRc-2) were obtained from about 300,000 plaques. After partial sequence determination by the M13 method, Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74:5463-5469; Messing et al. (1982) Gene 19:269-276, additional probes (nondegenerate 20-mers) were prepared and used to obtain clones pANPRc-4, 12, 13, 14, and 15 from the same cDNA library. Probes based on the pANPRc-4 sequence were used to obtain pANPRc-6 and probes based on the pANPRc-6 sequence used to obtain pANPRc-9 and 10. The total

-29-

frequency of ANP receptor clones in the cDNA library which were detected with various probes was about one per 20,000.

The ANP receptor cDNA clones are aligned by sequence in Figure 2B. The coding segment (open reading frame) is indicated by the bold line, while the sequences from individual clones are indicated below. Dashed lines indicate regions where sequence analysis is incomplete. In total, they define over 3558 nucleotides of mRNA sequence. The open reading frame is 1611 nucleotides in length. This includes an in-frame segment encoding the N-terminal amino acid sequence of Figure 2A. The sequences of the 5' ends of clones pANPRc-2, pANPRc-12 and pANPRc-15 are identical while those of pANPRc-13 and pANPRc-14 differ by 4 and 3 nucleotides, respectively. The 5' end of the ANP receptor mRNA thus appears to contain 465 noncoding nucleotides. Nearly 1500 nucleotides of 3' noncoding sequence have been obtained with over 500 more defined by partial sequence and mapping of pANPRc-9. None of the clones contain a poly(A) sequence indicative of an mRNA 3' terminus, although two potential poly(A) addition signals (AAUAAA) are present at 2440 and 3197 nucleotides. The receptor appears, therefore, to be encoded at the 5' end of a large (>4000 nucleotide) mRNA. This is similar to the mRNA structure of other receptors for polypeptides.

A clone containing the entire ANP receptor coding region was constructed in pGEM1 (Promega Biotec) by combining pANPRc-1 and pANPRc-4 utilizing a NcoI restriction site common to both. The resultant clone, pANPRc-1/4, contains a 2290 base pair DNA insert which includes the entire open reading frame, 233 nucleotides of the 5' noncoding region and 190 nucleotides of 3'

-30-

noncoding sequence. Restriction of the 3' plasmid/cDNA junction with EcoRI and subsequent transcription with SP6 polymerase resulted in a synthetic RNA of ~2300 nucleotides as determined by agarose gel electrophoresis.

5 The primary structure of the receptor was determined by analysis of the sequences of all the clones. The cDNA sequence and predicted amino acid sequence is shown in Figure 3. The numbers on the right indicate the nucleotide position in the sequence. The predicted amino acid sequence of the preproreceptor is indicated below the codons of the uninterrupted coding region. Amino acid numbers beginning with MET (001) are indicated. Several single nucleotide differences between different clones were noted, four of these in 10 the coding region. Nucleotides 552, 1010, 1436, and 1558 were G in pANPRc-2, C in pANPRc-1, and A in pANPRc-4, respectively. Since this frequency is similar to the error frequency associated with Reverse Transcriptase, Guidon et al. (1983) Meth. Enzymol. 20 101:370-386, it is likely that these differences are cloning artifacts. The sequence in Figure 3 represents the consensus of at least 2 clones in each position. Potential signal peptidase cleavage sites (A) and the beginning of the mature receptor N-terminus (L) are shown. Potential N-linked glycosylation sites are boxed and the putative transmembrane domain is denoted by the bar. Potential poly(A) addition signals in the 3' noncoding region are overlined.

30 An open reading frame 538 codons defines the primary structure of the bovine ANP receptor. The ANP receptor precursor polypeptide is thus predicted to be composed of 537 amino acids with a molecular weight of 59,744 daltons. Although the ATG shown as the initiation codon in Figure 3 is preceded by four



-31-

additional ATGs which could be start codons, the latter four are followed by stop codons in each reading frame as well as by a T-rich region which would encode an unlikely oligophenylalanine stretch in any frame. A  
5 good translation initiation signal (GCACG) as defined by Kozak ( $CC^A/GCC$ ), (1986) Cell 44:283-292, precedes the predicted ATG and this ATG is in frame with an oligopeptide sequence identical to the N-terminal sequence of the isolated receptor. The size predicted  
10 for the receptor precursor is in excellent agreement with the observed size of the in vitro translation product ( $M_r \sim 58,000$ ) of RNA synthesized using the cDNAs as template, and the amino acid composition of the purified receptor is also in good agreement with the  
15 predicted sequence. Finally, characteristics of the sequence are consistent with known and presumed characteristics of the receptor.

The hydropathicity profile of the receptor amino acid sequence was also calculated by the method of  
20 Kyte and Doolittle, (1982) J. Mol. Biol. 157:105-132. Local hydropathicity values were averaged from residue  $x-9$  to  $x+9$  and plotted versus residue  $x$  (Amino Acid #) as shown in Figure 4. Positive values indicate hydrophobic regions and negative values indicate  
25 hydrophilic regions. A schematic representation of the receptor protein is depicted below for reference. Filled-in regions indicate the putative signal and transmembrane sequences respectively. The stippled region denotes the area within which signal peptidase  
30 presumably cleaves and the open region denotes additional amino acids removed during receptor maturation. References sequences in the receptor are cysteine (C) and the Asn-X-Ser/Thr potential glycosylation sites (CHO).

-32-

E. coli (pANPRc-1) was deposited on 5 May 1986 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, U.S.A., under the terms of the Budapest Treaty on the Deposit of Microorganisms. The deposit has been assigned accession number 67105. To the extent of any discrepancies between the sequence shown in Figures 2A and 3, and the sequence contained in the deposited clone pANPRc-1, the latter is controlling.

10:

Example III

The following example describes the cloning of a full-length human ANP receptor coding sequence.

To obtain a human ANP receptor clone, a human kidney cDNA library was screened using nick-translated coding sequence of the bovine clone (a 1.4 kb fragment: pANPR-1). Of approximately  $1 \times 10^6$  members screened, 4 were positive. Three of these were independent overlapping clones of 1096 bp (clone 1-1-1), 925 bp (clone 12-1-2) and 813 bp (clone 16-1-1) having homology to the 1083 and 2121 bp region in the bovine clone. Relative to the bovine clone sequence, the clone 1-1-1 has a 3 bp deletion at 1873, and all three clones shown are identical 12 bp insertion in the 3' untranslated region. All three clones terminate at an EcoRI site and do not have a poly A tail.

Approximately  $0.5 \times 10^6$  members of a human placental cDNA library, when screened with 2 28-mer oligonucleotides (1119-1147 bp and 1166-1194 bp in human sequence) and a nick-translated 243 bp EcoRI/SacI fragment from clone 1-1-1 (pANPHRC2), gave one independent clone of 1636 bp (clone 4-2) having homology to the 96 to 1732 bp region in the bovine clone. This clone may have 12 bp insertion at 550 bp relative to the bovine clone.

-33-

pANPHRC4, a human receptor clone having full-length coding sequence, is made by ligation of the ca 1250 bp EcoRI/SacI fragment from clone 4-2 (pANPHRC1) and the ca 700 bp SacI/EcoRI fragment from clone 12-1-2 (pANPHRC3) into the EcoRI-digested and CIP-treated vector pUC9. Figure 5 shows this human receptor clone sequence with 5' untranslated region, signal sequence, initiating Met, coding region, 3' untranslated region, and amino acid differences from the bovine.

E. coli (pANPHRC1) and E. coli (pANPHRC3) were deposited on 8 May 1987 with the American Type Culture Collection under the terms of the Budapest Treaty on the Deposit of Microorganisms. The deposits have been assigned accession numbers 67401 and 67402, respectively. To the extent of any discrepancy between the sequence shown in Figure 5 and the sequence contained in these deposited clones, the latter are controlling.

20

#### Example IV

The following demonstrates that the ANP receptor described herein is found in a range of tissues known to exhibit ANP binding.

In order to determine whether the cloned sequence was expressed in tissues and cells known to display the ANP receptor, Northern blot analysis was performed. Cell lines were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum with 10% C)<sub>2</sub> at 37°C until confluent. Poly(A) RNAs were isolated by the guanidine isothiocyanate method, Chargwin, et al. (1979) Biochem. 18:5294-5299, followed by oligo(dT) cellulose chromatography. RNA was denatured in formamide and formaldehyde at 50°C and then separated on a 1.4% agarose gel containing formaldehyde and transferred to nitrocellulose. The filters were

-34-

hybridized in 50% formamide plus 5X SSC to pANPRc-1 insert DNA made radioactive by nick translation. Filters were washed at 65°C in 1X SSC plus 0.1% SDS and subjected to autoradiography.

5 Poly(A)-containing RNAs homologous to the cloned sequence are present as discrete species in three bovine primary cell lines which display ANP receptors: aortic endothelial cells (BAE), adrenal cortical cells (BAC), and the aortic smooth muscle cells (BASM) from  
10 which the cDNA clones were derived.

Since kidney and adrenal tissues also express ANP receptors, poly(A) RNAs isolated from these tissues were analyzed. Bovine kidney RNA was found to contain discrete RNA species homologous to the cloned sequence  
15 with fractionated papillae and cortex showing virtually identical patterns. These results are consistent with UV-photoaffinity labeling studies which show that the Mr ~60,000 ANP binding subunit is present in both  
glomerulus and inner medullary collecting duct regions  
20 of the kidney. The analysis was unable to detect receptor message in RNA from whole adrenal, however.

An additional result of the Northern analysis is that at least four discrete RNA species are present in the cultured cells. The major receptor RNA apparent  
25 in BAC and BAE cell RNAs is ~8000 nucleotides in length, but a ~3100 nucleotide RNA is also detected, and minor bands can be seen at ~4000 and ~5000 nucleotides. The 8000 nucleotide RNA is not an unspliced pre-mRNA since it is found in RNA fractionated  
30 to remove nuclear RNAs. The smaller RNAs are also not likely discrete degradation products since they contain both the 5' end and a poly(A) tail, as evidenced by the fact that they are detected equally with probes to 5' coding or 3' coding regions and were isolated by oligo(dT)-cellulose chromatography.

-35-

Heterogeneity of ANP receptor mRNAs could be the result of alternative splicing or transcription of different genes. Since the different species cannot be distinguished by increasing hybridization wash stringencies, they are not the product of relatively divergent genes. Also, given that only a single mRNA species (~5600 nucleotides) is detected in human tissues, receptor mRNA heterogeneity in the cow is of questionable functional significance. Length heterogeneity is frequently observed among receptor mRNAs, and may well be due to differences in lengths of 3' noncoding regions as has been shown for the IL-2 receptor mRNAs. The data above and the presence of two potential poly(A) addition signals in the 3' noncoding region of the ANP receptor clones suggest that length differences in ANP receptor mRNAs is due to differences in lengths of 3' noncoding regions.

#### Example V

The following example describes the expression of recombinant ANP receptor in a heterologous mammalian cell, as well as in vitro transcription of ANP receptor mRNA.

To demonstrate that pANPRC-1/4, actually encodes the ANP receptor, it was tested for its ability to elicit specific ANP binding in a heterologous system, Xenopus oocytes. The receptor coding sequence from pANPRC-1/4 was cloned into pGEM1 (ProMega, Madison, WI) and RNA prepared according to the supplier's instructions. Oocyte preparation and injection were performed essentially as described, Gurdon et al. (1983) Meth. Enzymol. 101:370-386. Typically, each oocyte was injected with 50nl containing 50nl synthetic RNA

-36-

followed by incubation in modified Barth's saline at 21°C for 48 hr. Crude membranes were prepared and solubilized in receptor binding buffer (2 mg/ml C<sub>12</sub>E<sub>8</sub>, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 10 mM CaCl<sub>2</sub> and 100 mM Tris:HCl; pH 7.5). Binding was measured after incubating 0.5 ml of membrane suspension containing 10 µg protein with 2 x 10<sup>5</sup> cpm of [<sup>125</sup>I] rANP (1 x 10<sup>3</sup> cpm/fmol) and the indicated concentration of unlabeled ANP analog for 30 min at 21°C. Reactions were terminated and free peptide separated from bound by precipitation with acetone (40% v/v final). Counts bound in the absence of unlabeled ligand were 2048 +/- 374 cpm while nonspecific binding (counts bound in the presence of 20nM rANP) were 592 +/- 89 cpm. Bombesin (Peninsula Labs) has no effect on binding even at 100µM.

Only low level, nonspecific binding was detected in membranes of uninjected or mock injected eggs. However, saturable, specific binding of radiolabeled ANP was demonstrated in solubilized membranes of oocytes which had been injected with synthetic mRNA. Both rANP (4-28) and the truncated analog rANP (4-28) for binding. The I<sub>1</sub> apparent obtained from the experiment was 0.27 nM for both analogs. Binding was specific for ANP analogs since bombesin, an unrelated tetradecapeptide, did not compete for binding. In vitro transcription of the ANP receptor coding region of pANPRc-1/4 and subsequent translation in a cell free reticulocyte lysate demonstrated that the synthetic RNA was a functional mRNA encoding an Mr ~58,000 polypeptide as judged by SDS-polyacrylamide gel electrophoresis.

-37-

Example VI

This example is directed to a protocol useful in the expression of coding sequences obtained according to Examples II, III or VIII.

5 cDNA clones encoding ANP receptor protein are most conveniently used to produce recombinant proteins in a variety of hosts, as described above. Expression in mammalian systems, however, is favored, as the host is capable of post-translational processing analogous to  
10 that experienced by natively produced protein. Thus, either cDNA or genomic sequences may be used.

A full-length cDNA (Example II or III) or genomic (Example VIII) ANP receptor-encoding clone is prepared for insertion into a host vector. The cloned  
15 insert is excised with EcoRI by partial digestion when the insert itself contains EcoRI sites. If necessary, other appropriate enzymes can be used, and the insert provided with EcoRI linkers. Then the excised insert is placed into the host vector pHS1, as described below.

20 The plasmid pHS1 is suitable for expression of inserted DNA in mammalian hosts. It contains 840 bp of the hMT-II sequence from p84H (Karin et al., (1982) Nature 299: 297-802) which spans from the HindIII site at position -765 of the hMT-II gene to the BamHI  
25 cleavage site at base + 70. To construct pHS1, plasmid p84H was digested to completion with BamHI, treated with exonuclease BAL-31 to remove terminal nucleotides, and then digested with HindIII. The desired 840 bp fragment was ligated into pUC8 (Vieira et al., (1982) Gene 19:  
30 259-268) which had been opened with HindIII and HincII digestion. The ligation mixture was used to transform E. coli HB101 to Amp<sup>R</sup>, and one candidate plasmid, designated pHS1, was isolated and sequenced by dideoxy sequencing. pHS1 contains the hMT-II control sequences

upstream of a polylinker containing convenient restriction sites.

The ANP receptor subunit coding sequence, prepared as above, is ligated into EcoRI digested pHS1 and the ligation mixture used to transform E. coli MC1061 to Amp<sup>R</sup>. Successful transformants are screened by restriction analysis, and a strain containing the desired plasmid, pMT-ANPr is further propagated to prepare quantities of plasmid DNA.

Chinese hamster ovary (CHO)-K1 cells are grown on medium composed of a 1:1 mixture of F12 medium and DME medium with 12% fetal calf serum. The competent cells are co-transformed with pMT-ANPr and pSV2:NEO (Southern et al., (1982) J. Mol. Appl. Genet. 1: 327-341). pSV2:NEO contains a functional gene conferring resistance to the neomycin analog G418. In the transformation, 500 ng of pSV2-NEO and 5 µg of pMT-ANPr are applied to a 16-mm dish of cells in a calcium phosphate-DNA co-precipitate according to the protocol of Wigler et al., (1979) Cell 16: 777-785, with the inclusion of a two minute "shock" with 15% glycerol after four hours of exposure to the DNA. A day later, the cells are subjected to 1 mg/ml G418 to provide a pool of G418-resistant colonies, which are assayed for ANP receptor production and then cloned out.

Successful transformants, also having a stable inheritance of pMT-ANPr, are plated at low density for purification of clonal isolates. Small amounts of these isolates are grown in multi-well plates after exposure to  $10^{-4}$  M zinc chloride for convenient assay of ANP receptor production. ANP receptor determinations are made by standard ELISA or radioimmunoassays against antisera prepared against the appropriate ANP receptor protein using standard methods. Clonal isolates which



-39-

produce large amounts of the desired ANP receptor are selected.

The cells, which are shown to produce ANP receptor under suitable conditions, are then seeded at 1/10 confluency in basal medium supplemented with 10% fetal calf serum, incubated overnight, and then induced for ANP receptor production by addition of zinc chloride in the concentration range of  $1 \times 10^{-4}$  M to  $3 \times 10^{-4}$  M. ANP receptor levels rise for 7-10 days, under optimal inducing conditions,  $2 \times 10^{-4}$  M  $\text{ZnCl}_2$ .

If desired, the ANP receptor secreted into the medium can be purified according to the procedures set forth above for the native protein, or by other standard methods known in the art.

#### Example VII

This example provides a protocol for the expression of intron-free DNA sequences encoding ANP receptor protein subunit in procaryotic systems.

A convenient host vector for expression is pKT52, which contains the "trc" promoter, followed by an ATG start codon. The construction of pKT52 is described in commonly owned U.S. serial no. 616,488 (filed 1 Jun 1984), the disclosure of which is incorporated herein.. Briefly, the "trc" promoter contains the upstream portions of the trp promoter and the downstream, operator-containing, regions of the lac promoter and was originally prepared from two readily available plasmids containing these promoters. To construct the trc promoter as a BamHI/HindIII cassette, an intermediate plasmid pKK10-0 was prepared containing the hybrid promoter.

To prepare pKK10-0, pEA300 (Amman et al., (1983) Gene 25:167-178) was digested with PvuII and

-40-

Clal. filled in using dCTP only in the presence of DNA polymerase (Klenow), followed by digestion with mungbean nuclease, and the large vector fragment isolated. This vector fragment contains the upstream portions of the trp promoter. The fragment was ligated with a 55 bp blunt-ended HpaII/PvuII digest excised from pGL101 (Lauer et al., (1981) J. Mol. Appl. Genet. 1:139-147), which was prepared by digesting pGL101 with PvuII and HpaII followed by repair in the presence of dGTP and labeled dCTP. This fragment contains the lac operator region. The ligation product of these two blunt-end fragments was pKK10-0.

A BamHI site was inserted into pKK10-0 upstream of the trp/lac (trc) promoter/operator by digestion with EcoRI, filling in with Klenow, and insertion of the BamHI linker 5'-CCGGATCCGG-3'. The resulting plasmid, pKK10-1 was digested with PvuII, and ligated to the NcoI linker, 5'-ACCATGGT-3', digested with NcoI, filled in, and then ligated to a double-stranded linker containing PstI and HindIII sites provided as two complementary oligonucleotides, 5'-GCTGCAGCCAAGCTTGG-3' and its complement. The ligation mixture was used to transform E. coli to Amp<sup>R</sup>. The isolated plasmid DNA was digested with BamHI and HindIII, and the small BamHI/HindIII fragment obtained on electrophoresis contains the trc promoter.

To complete pKT52, the BamHI/HindIII fragment containing the trc promoter was ligated into the large fragment obtained from BamHI/HindIII digestion of pKK10-2 (Brosius, (1984) Gene 27:161-172) which contains the Amp<sup>R</sup> gene and the origin of replication. The resulting plasmid, pKK233-1 was digested to completion with PvuI and then partially with BglI and ligated with the 360 bp PvuI/BglI fragment containing the

-41-

corresponding portion of the ampicillin resistance gene but lacking a PstI site from pUC8. The ligation mixture was used to transform E. coli and transformants were screened for the presence of only one PstI site next to the trc promoter. pKK233-2, which met the criteria, was digested with EcoRI and PvuII, filled in with dATP and dTTP, and religated to obtain the correct construction. pKT52, which contains the desired trc promoter, a downstream ATG start codon, and downstream NcoI, PstI and HindIII sites.

For construction of expression vectors, the receptor-encoding cDNA is obtained by excising with EcoRI or other appropriate enzyme digestion, and if necessary, modifying the appropriate fragment. The 3' end is prepared for insertion into pKT52 by cutting downstream of the termination codon at any convenient restriction site and supplying PstI or HindIII linkers. The 5' end is prepared by cutting at a site inside the coding sequence and supplying the missing codons and an NcoI site using a synthetic DNA, or by providing an appropriately located NcoI site by mutagenesis. The resulting NcoI/HindIII or NcoI/PstI fragment is then ligated into NcoI/HindIII-digested pKT52 or NcoI/PstI digested pKT52 to provide the ANP receptor-encoding cDNA in reading frame with the ATG start codon.

For bacterial expression, the resulting expression vectors are used to transform E. coli MC1061 or other appropriate host cells to Amp<sup>R</sup>, and the transformed cells are then grown on M9 medium containing 1 mM IPTG for 3-5 hr to an O.D. of 0.2-0.5. (IPTG is a standard inducer for control sequences regulated by the lac operator.) The cells are then harvested, lysed by sonication or treatment with 5% trichloroacetic acid, and the cell extracts assayed for the desired ANP

-42-

receptor protein. The receptor protein can be purified from the extracts by methods used for the native protein or by other procedures known in the art.

5

Example VIII

This example is directed to a method of probing a human genomic library to obtain clones encoding ANP receptor protein.

A human genomic library is prepared in  $\lambda$  Charon 4A, as described by Lawn et al., (1978) Cell 15:1157-1174. Portions of the cDNA inserts encoding bovine vascular ANP receptor (Example II) are prepared for use as probes by excising the cDNA from pANPR-1, and nick-translating the isolated insert, or some portion of it. The cDNA probes are hybridized to filters containing about 1 million recombinant phage from the library, as described for the 51-mer probe in Example II, except that the hybridization mixture contains 40% formamide, and the filters are held at a constant 45°C overnight. These filters are then washed twice for 1 hour at 65°C in 2xSSC, 0.1% SDS. Recombinant phage containing human ANP receptor sequences are indicated by phage strongly hybridizing to the probe.

Related receptor genes can also be identified by using the same hybridization and wash conditions, except that the hybridization temperature is 35°C, and the wash temperature is 50°C. Strongly hybridizing positives containing genomic ANP receptor genes will remain, while weaker hybridizing probes indicate the related receptors.

If no positives appear, Southern hybridizations can be used to help define the appropriate screening conditions. First, Southern hybridizations are carried out with 10  $\mu$ g of human DNA per lane, the human DNA

-43-

being digested with various restriction enzymes (e.g., EcoRI, PstI, BamHI, and HindIII). Filters are then hybridized in the least stringent conditions (30% formamide) and washed under the lower stringency 50°C wash described above. If the lanes in the Southern hybridization contain streaks of hybridization with no distinct bands above the background, the wash temperature is adjusted (up to 65°C) until multiple bands appear. Some bands will be stronger and some fainter, representing the gene for the homologous receptor and gene(s) for related receptors, respectively. More formamide (e.g., 40%) in the hybridization mixture of another Southern, followed by washing at the temperature found in the previous Southern, should reveal distinct bands with lowered background, with only the stronger bands showing. If the weaker bands are still showing, the formamide can be adjusted to a still higher concentration, for example, to 50%.

Mammalian genomic libraries, therefore, can be screened under appropriate conditions as defined in the above-described Southern hybridizations. Genomic coding sequences for ANP receptor protein isolated in the screening can then be employed in the expression protocol described in Example VI.

#### Example IX

This example provides a protocol useful for the production of monoclonal antibodies to ANP receptor protein.

Hybridomas can be prepared from B-cells which have been stimulated by antigen in tissue culture. First, thymocyte-conditioned medium is prepared. Two thymuses from 4-6 week old transgenic mice (e.g., Balb/c

-44-

- and C57) are incubated in a standard medium containing 1:1 DMEM:RPMI medium supplemented with 1% (v/v) Nutricyte® (Enzymes International, San Diego). After 48 hr incubation, the medium is centrifuged at 2,000 x g for 10 min and the cell pellet discarded. See generally Luben et al., (1980) Molec. Immunol. 17:635-639. One part thymocyte-conditioned medium is then combined with 2 parts of the standard medium supplemented with Nutricyte® to give a final volume of about 10 ml.
- 10 Then 0.05-1.0 µg of purified ANP receptor protein is added (Example I). The combination is then incubated for 96 hr at 37°C in a CO<sub>2</sub>-humidified incubator. At the conclusion of incubation, activated B-cells are fused with an appropriate partner (e.g., P3X63Ag8.653 or 15 Sp2/O-Ag14) to produce hybridomas by standard procedures. See, e.g., Kohler et al., (1975) Nature 256:485-496. Successful hybridomas are screened for production of the desired monoclonal antibodies by routine procedures. See, e.g., U.S. Patent No. 20 4,562,003.

#### Example X

This example provides an assay for measuring ANP activity in a sample, such as human blood.

- 25 A frozen sample of pure receptor (Example I) is diluted in an appropriate buffer, such as 100 mM Tris, pH 7.5, 100 mM NaCl, 10 mM CaCl<sub>2</sub>, 10 mM MgCl<sub>2</sub>, 2 mg/ml C<sub>12</sub>E<sub>8</sub>, and the equivalent of approximately 0.5 pmol <sup>125</sup>I-ANP binding sites is aliquoted per tube.
- 30 Approximately 0.5 ml of binding buffer containing <sup>125</sup>I-ANP (4.0 nM, spec. act. = 200 cpm/fmol) is then added. A standard curve is constructed using various concentrations of unlabeled ANP (0.05 - 100.0 nM). Unknown samples are then added in place of unlabeled

-45-

ANP. Separation of receptor-bound  $^{125}\text{I}$ -ANP from free ligand is accomplished by adding acetone (final concentration = 37% v/v) followed by centrifugation at 500 x g for 10 min at 4°C, followed by aspiration of the supernatant. The tubes can be counted on a gamma counter and a standard competition curve can be constructed (see Figure 1).

Modifications of the above embodiments are readily apparent to and within the skill of the ordinary artisan. Thus, it is intended that the present invention be limited only by the scope of the appended claims.

15

20

25

30

-46-

Claims

1. A cell-free composition comprising mammalian Atrial Natriuretic Peptide (ANP) receptor protein subunit having a molecular weight of about 60,500 daltons, said receptor protein subunit comprising a minimum of about 75% by weight of the protein in said composition.
2. A composition according to claim 1 wherein said receptor protein subunit is bovine ANP receptor protein subunit.
3. A composition according to claim 1 wherein said receptor protein subunit is human ANP receptor protein subunit.
4. A composition according to claim 1 wherein said receptor protein subunit is a synthetic ANP receptor protein.
5. A cell-free composition containing a protein binding Atrial Natriuretic Peptide (ANP), said protein (i) having an amino acid sequence homology of at least about 75% to the mammalian 60.5 kd ANP receptor protein subunit, (ii) exhibiting a binding affinity to ANP (4-28) of  $\leq 10\text{nM}$  when solubilized in a dimeric form, and (iii) comprising a minimum of about 75% by weight of the protein in said composition.
6. A method of purifying native ANP receptor protein comprising:
  - (i) providing a membrane-containing cell fraction prepared from mammalian cells having ANP receptors;



-47-

- (ii) solubilizing ANP receptor protein in said membrane fraction with  $C_{12}E_8$  detergent to produce a supernatant containing said ANP receptor protein; and
- (iii) purifying ANP receptor protein from said supernatant by passing said supernatant through a chromatographic column containing immobilized ANP under conditions whereby said ANP receptor protein is bound to said immobilized ANP, followed by eluting bound ANP receptor protein from said column to provide purified ANP receptor protein.

7. A method of isolating DNA sequences encoding ANP receptor protein comprising:

- (i) providing a DNA library prepared from a mammalian cell source;
- (ii) screening said DNA library by hybridization with an oligonucleotide probe containing codons for an amino acid sequence homologous to a selected region of an ANP receptor protein subunit; and
- (iii) isolating DNA molecules from said DNA library to which said oligonucleotide selectively hybridizes.

8. A composition comprising a recombinant vector containing a DNA sequence encoding an amino acid sequence homologous to the 60.5 kd mammalian ANP receptor protein subunit, said composition being substantially free of recombinant vectors that do not contain said DNA sequence.

9. A DNA molecule encoding an amino acid sequence homologous to the 60.5 kd mammalian ANP receptor protein subunit, said molecule being free of DNA molecules that do not encode said amino acid sequence.

-48-

10. A recombinant DNA vector capable of transforming a selected host cell comprising a DNA coding sequence encoding an amino acid sequence homologous to the 60.5 kd mammalian ANP receptor protein subunit, said coding sequence being oriented with respect to a DNA control sequence in said vector so that said coding sequence is transcribed in a host cell transformed by said vector.
11. A vector according to claim 10 wherein said host cell is procaryotic.
12. A vector according to claim 10 wherein said host cell is eucaryotic.
13. A procaryotic cell transformed by the vector of claim 11, or progeny thereof.
14. A eucaryotic cell transformed by the vector of claim 12, or progeny thereof.
15. A mammalian cell transformed by the vector of claim 12, or progeny thereof.
16. A method of producing ANP receptor protein subunit comprising growing the cell of claim 13 under conditions whereby a peptide comprising ANP receptor protein subunit is expressed, and recovering said peptide.
17. A method of producing ANP receptor protein subunit comprising growing the cell of claim 14 under conditions whereby a peptide comprising ANP receptor protein subunit is expressed, and recovering said peptide.

-49-

18. A composition comprising anti-ANP receptor protein antibodies substantially free of other antibodies.

5           19. An immortal mammalian cell line producing the antibodies of claim 18.

          20. A method of purifying ANP receptor protein comprising:  
10           (a) providing a solution containing said receptor protein;  
          (b) contacting said solution with immobilized anti-ANP antibodies according to claim 11;  
          (c) separating said immobilized antibodies from  
15 said solution after said contacting step; and  
          (d) recovering ANP receptor protein from said immobilized antibodies after said separating step.

20

25

30

1/9




FIG. I

SUBSTITUTE SHEET


FIG. 2A

Exr Ala Leu Pro Pro Gln Lys Ile Glu Val Leu Val Leu Leu Pro Gln Asp  
Asp Ser Tyr Leu Phe Ser Leu Ala Arg Val Arg Pro Ala Ile Glu

1. GTT TTT TAT TAT CA  
C C A C
  2. GTT CTA CTA AGA AT  
C G G C
- T  
TCA  
G

3. GTC TTC TAG CTC CAC GAC GAC GAC GGG GTC CTC CTG AGG ATG GAC AAG  
A A TCG

FIG. 2B



3/9

FIG. 3-1

|      |   |      |
|------|---|------|
| 1    | GCG CGA ATC AAT GAG ATC AAA CCG GAG GGA GAT GCA CCG TCA ATT ACA AGC ACT TGG ACA AGT CTA ACT TTT TCT | 75   |
| 76   | TCT TTT ACA AAT GCT CTT TCC AAA GCA AGC TTA GCA ACG CCA TAT AAG AAG CCA CTT CTA AGC AAA ATA GCT ATA | 150  |
| 151  | TAT CAA GGG AGG GCT AAT CTA TGT ATT TAT AAA AAG TAT ATA TAT AAT ATA CTA TAG GAG TAC AGG TTT ACA     | 225  |
| 226  | CCC AGT TAA CTT TTT CTT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT TCT     | 300  |
| 301  | TCT TCC TCT CTT TTT GCG AGT TAG TGA AGG GGG TAT TCT TTT ATT TTT TCT TAG AGC GCC CAA GGG GCG GAG GAA | 375  |
| 376  | CCT CGG AGA GGA GTT GGG GAG TTA AGA GGT AGG GTG GGT GGG GGG CAG AGG GCG CAG CGA GGG CAG GCG         | 450  |
| 451  | CTT TCC TGC GGC ACG ATG CCG TCC CTA CTG GTG CTC ACT TTC TCC GCG TGC CTC GGT TGG GCG TTA CTG         | 525  |
|      | Met Pro Ser Leu Leu Val Leu Thr Phe Ser Ala Cys Val Leu Leu Gly Trp Ala Leu Leu                     |      |
| 001  |   |      |
| 526  | GCC GAC TGC ACT GCG GGC GGT GGC AGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC         | 600  |
|      | Ala Asp Cys Thr Gly Gly Gly Ser Gly Gly Ala Gly Pro Gly Arg Gly Arg Glu Arg Glu Ala Leu Pro         |      |
| 601  | CCG CAG AAG ATC GAG GTT CTG GTG CTG TTT CCG CAG GAC TCT TAC CTG TTC TCC CTT GCT CCG GTG CGA CCG     | 675  |
|      | Pro Gln Lys Ile Glu Val Leu Val Leu Leu Pro Gln Asp Ser Tyr Leu Phe Ser Leu Ala Arg Val Arg Pro     |      |
| 050  |   |      |
| 676  | GCC ATA GAG TAC GCG CTG CCG ACG GTG GAG GGC AAC GCG ACC GGG CCG CTC CTG CCA GCC GGC ACT CCG TTC     | 750  |
|      | Ala Ile Glu Tyr Ala Leu Arg Thr Val Glu Gly Asn Ala Thr Gly Arg Arg Leu Leu Pro Ala Gly Thr Arg Phe |      |
| 751  | CAG GTG GCC TAC GAA GAC TCG GAC TCG GGC AAC CCG GCA CTC TTC AGC CTG GTG GAC CCG GTG GCG GCG CCG     | 825  |
|      | Gln Val Ala Tyr Glu Asp Ser Asp Cys Gly Asn Arg Ala Leu Phe Ser Leu Val Asp Arg Val Ala Ala Arg     |      |
| 100  |   |      |
| 826  | GGA GCC AAG CCG GAT CTC ATC CTG GGG CCG GTG TGC GAG TAC CCG GCG CCG GTG GCT CCG CTA GCG TCG CAC     | 900  |
|      | Gly Ala Lys Pro Asp Leu Ile Leu Gly Pro Val Cys Glu Tyr Ala Ala Pro Val Ala Arg Leu Ala Ser His     |      |
| 901  | TGG GAC CTC CCC ATG CTG TCT GCC GGG GCC CTG GCA GCC GGC TTC CAG CAT AAG GAC ACG GAG TAC TCG CAC CTT | 975  |
|      | Trp Asp Leu Pro Met Leu Ser Ala Gly Ala Leu Ala Met Leu His Lys Asp Thr Glu Tyr Ser His Leu         |      |
| 150  |   |      |
| 976  | ACG CGC GTG GCA CCC TCG TAC GCC AAG ATG GGC GAG ATG ATG CTC GCC CTG TTC CCG CAC CAG TGG AGC CCG     | 1050 |
|      | Thr Arg Val Ala Pro Ser Tyr Ala Lys Met Gly Glu Met Met Leu Ala Leu Phe Arg His His Gln Trp Ser Arg |      |
| 1051 | GCC GTG CTG TAC ACC GAC GAC AAG CTG GAG CCG AAC TGC TTC ACC CTC GAG GGG GTC CAT GAG GTC TTC         | 1125 |
|      | Ala Val Leu Val Tyr Ser Asp Lys Leu Glu Arg Asn Cys Phe Phe Thr Leu Glu Gly Val His Glu Val Phe     |      |
| 200  |   |      |
| 1126 | CAG GAG GAA GGC TTG CAC ACG TCC GCC TAC AAT TTC GAT GAG ACC AAA GAC TTG GAT CTG GAG GAC ATC GTG CCG | 1200 |
|      | Gln Glu Glu Gly Leu His Thr Ser Ala Tyr Asn Phe Asp Glu Thr Lys Asp Leu Asp Leu Glu Asp Ile Val Arg |      |

4/9

## FIG. 3-2

1201 CAC ATC CAG GCC AGT GAG CGA GTG GTG ATC ATG TGT GCG AGT AGC GAC ACC ATC CGG GGG ATC ATG CTG GCG GCG 1275  
 His Ile Gln Ala Ser Glu Arg Val Ile Met Cys Ala Ser Ser Asp Thr Ile Arg Gly Ile Met Leu Ala Ala  
 250  
 1276 CAC AGG CAC CGA ATG ACC AGC GGG GAC TAC GCC TTC TTC AAC ATC CAG CTC TTC AAC AGC TCC TTC TAT GGA GAT 1350  
 His Arg His Gly Met Thr Ser Gly Asp Tyr Ala Phe Phe Asn Ile Glu Leu Phe Asn Ser Ser Phe Tyr Gly Asp  
 1351 GGC TCG TGG AAG AGA GGA GAC AAA CAC GAC TTT GAA GCT AAG CAA GCG TAC TCA TCC CTC CAA ACA ATC ACT CTA 1425  
 Gly Ser Trp Lys Arg Gly Asp Lys His Asp Phe Glu Ala Lys Gln Ala Tyr Ser Ser Leu Gln Thr Ile Thr Leu  
 300  
 1426 CTG AGG ACA GTG AAA CCT GAG TTT GAG AAG TTT TCC ATG GAG GTG AAA AGT TCT GTT GAG AAG CAA GGG CTC AGT 1500  
 Leu Arg Thr Val Lys Pro Glu Phe Glu Lys Phe Ser Met Glu Val Lys Ser Ser Val Glu Lys Gln Gly Leu Ser  
 1501 GAG GAA GAT TAC GTG AAC ATG TTT GTT GAA GGA TTC CAC GAT GCC ATC CTC CTC GTG GCT TTA CGT GAA 1575  
 Glu Glu Asp Tyr Val Asn Met Phe Val Glu Gly Phe His Asp Ala Ile Leu Leu Tyr Val Leu Ala Leu Arg Glu  
 350  
 1576 GTA CTC AGA GCT GGT TAC AGT AAG AAG GAT GGA GGG AAA ATT ATC CAG CAG ACT TGG AAC CGA ACA TTT GAA GGT 1650  
 Val Leu Arg Ala Gly Tyr Ser Lys Lys Asp Gly Gly Lys Ile Ile Gln Gln Thr Trp Asn Arg Thr Phe Glu Gly  
 400  
 1651 ATT GCT GGG CAG GTC TCC ATA GAT GCC AAC GGA GAC CCG TAT GGG GAT TTC TCT GTG ATC GCC ATG ACT GAG ACA 1725  
 Ile Ala Gly Gln Val Ser Ile Asp Ala Asn Gly Asp Arg Tyr Gly Asp Phe Ser Val Ile Ala Met Thr Asp Thr  
 450  
 1726 GAA GCG GGT ACC CAG GAG GTT ATT GGT GAT TAC TTT GGA AAA GAA GGT CGT TTT GAA ATG CCG CCG AAT GTC AAA 1800  
 Glu Ala Gly Thr Gln Glu Val Ile Gly Asp Tyr Phe Gly Lys Glu Gly Arg Phe Glu Met Arg Pro Asn Val Lys  
 1801 TAT CCT TGG GGA CCT TTA AAA CTG AGA ATA GAT GAA ACC AGA ATG GTG GAG CAC ACG AAC AGC TCT CCT TGC AAA 1875  
 Tyr Pro Trp Gly Pro Leu Lys Leu Arg Ile Asp Glu Thr Arg Met Val Glu His Thr Asn Ser Ser Pro Cys Lys  
 450  
 1876 GCA TCA GGT GGC CTA GAA GAA TCA GCG GTG ACA GGA ATT GTT GTG GGG GCC TTA CTA GGA GCT GGT TTG CTA ATG 1950  
 Ala Ser Gly Gly Leu Glu Glu Ser Ala Val Thr Gly Ile Val Val Gly Ala Leu Leu Gly Ala Gly Leu Leu Met  
 1951 GCC TTC TAC TTC TTC AGG AAG AAA TAC AGA ATA ACC ATT GAG AGG CGA AAC CAG CAA GAA GAA AGC AAC GTT GGA 2025  
 Ala Phe Tyr Phe Phe Arg Lys Lys Tyr Arg Ile Thr Ile Glu Arg Arg Asn Gln Gln Glu Ser Asn Val Gly  
 501  
 2026 AAA CAT CCG GAG TTA CCG GAA GAT TCC ATC AGA TCC CAC TTT TCG GTG GCT TAA AAG GAA GTC TGT TGT TTT GGC 2100  
 Lys His Arg Glu Leu Arg Glu Asp Ser Ile Arg Ser His Phe Ser Val Ala End  
 2101 TTG AGA TTC TTT AAG GAG ATA GAT GGG ATG AAA GAC ATC AAT GGA ATA GAA GGG GCG CTC TTG AAA AAC TCA TTC 2175  
 2176 TTT TAA GCA GTT AGT AAT TTT GTT ATA AAA TTT CTT TAG AAG CTC AGG AAC TAT TAT TAA TCA CCA TAT GCC CGC 2250

1201 1276 1351 1425 1500 1575 1650 1725 1800 1875 1950 2025 2100 2175 2250

5/9


FIG. 3-3

2251 TGG CCT CTC ATC TCA TGA CAA ACA AAC ACA GAG TCT GAG GTC TCC ATA TAA CAT CAC TCC TAA ATG TTG ATT CTG TTT CAA GGG CAT 2325  
2326 ATG ATT AGA TTT ATG TTC TGA AAG TCT GAG GTC TCC ATA TAA CAT CAC TCC TAA ATG TTG ATT CTG TTT CAA GGG CAT 2400  
2401 TAA AAT GTG TTT TAC TTA TAC TTA AAG TCT GAG ATG TTT TAT AGC TAG TAG AAT AAA ATC ATT TTT ACA TGT AGG ATA TTA TTG AAA 2475  
2476 AGG ATT TAA CCC CAA GAA GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT 2550  
2551 CTG GTT GGA GGG ATC TGA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA GGT CAA 2625  
2626 GAA TTT CCC CCA CCT CTT TCA GTG TCT TGT AAG AGC TAC TTT GGA AAG TTG TAA TTA TGA ATG AGA TAA GAG GAT 2700  
2701 TTA TGC AGA AAA AGC AAA TCT AAC TAT TTC ACT TTT TAA AAT ATA AAA AAC CCT ATT TCA CAC TAA CAT TTT ATT 2775  
2776 TTT AAG TAT TTT AAT CTT ATA TTT TCC TAT TAG AAA ATG TGT CTA TTT TTT CAT TTT GAA GAT TAA ATT TCA CTT 2850  
2851 ATA TTT TAA AAA CAT GGG TAA TGT GTA CAG CAA ACC CAA TAA TGA TGA AAG GAT GCC CTC TCT TTT TTT CTC CCT 2925  
2926 GTT TCC CTC TTC CCT GTG GCC ATA GCC CAA TAC GAA TTG CTG CTT GAA CTA CAG AGA TCT AGA AAT GTG TTC GGA 3000  
3001 TTG TAG ACT CTA CAG GAA TAC AGT TTA CTT GTT TTA AAT GCA AGC TAT TTT AGG ATA GTC TCC TTC CAG TTC 3075  
3076 TGG CCA AAG GAT GAA ATT TAT TAG AAT TAA GTC AGG TTT TAT AAA GGG AGG CAA CCT TTT TTT CTC AAG AAC 3150  
3151 TTT ATA GAG AGT TAG AAC TTG GCA GTA CGC ATA GAA ATG ATA ATT TAA TAA ATG ACA TTT TAC CAA AAT TGA CGA 3225  
3226 TTA TGA TTT TGG TTA AAA GAG GGA ATC TAA ACA GGT ACT ATG TTC CCT TTT AGT AAA CAC CGC AGA ACT TTG CAG 3300  
3301 TCA TCC ACT AAT AAC TTG TGT AAC AGG GGT TGG GTA CGG ATA TCA GGA ATT GGT CAA GGT TGA ATA ATT ATT TGC 3375  
3376 CGA ATC TCA ACT TTG CAC CAA GTA CTC TGT GTA TAG GGT TTA AGC TTA GGT TGC CAC TTT CAT GTA TAA TTT 3450  
3451 GTG GAG AAA ACA GAC AGT GAG GGA AGA ATG GGA AGT TGC CAG ATC GGT GTA CTA TCT TAT AAT GAT ATC ATG AAG 3525  
3526 GTG CTT CCT CAA TAA TGT TTG GAG CAT CTG GAA 3558



6/9

FIG. 4



SUBSTITUTE SHEET

7/9

FIG. 5-1

|   |            |   |            |            |            |            |
|---|------------|---|------------|------------|------------|------------|
| 10  | 20         | 30  | 40         | 50         | 60         | 70         |
| GAATTCGCAT  | GGTCGACTAC | ACGCCCAAT   | AAGAAGCCAC | CTCTAAGCAA | AATAGCTATA | TGTATAAACG |
| 80  | 90         | 100   | 110        | 120        | 130        | 140        |
| GAGGGCGAAT  | ATATACAAGT | ATATATATAT  | GTATATTACA | GACGCACAGG | TTTACACCCG | GTGAACTTTT |
| 150   | 160        | 170   | 180        | 190        | 200        | 210        |
| TCTTTTCTT   | TTTCTTTTTC | CTTTTCTTTT  | AAGAAAACT  | AGTGACATTG | CAGAGAAGGA | CGCTTCCTCT |
| 220   | 230        | 240   | 250        | 260        | 270        | 280        |
| CTATCTTTTG  | GCGCATTAGT | GAAGGGGGTA  | TTCTATTTTG | TTAAAGCGCC | CAAGGGGACC | GGAACCTTG  |
| 290   | 300        | 310   | 320        | 330        | 340        | 350        |
| GAGAGAAGAG  | TGGGGAGGAA | AGAGGAAGGG  | TGGGTGGGGG | GCAGAGGGCG | AGTCGGCGGC | GGCGAGGGCA |
| 360   | 384        | 399   |            |            |            |            |
| AGCTCTTTCT  | TGCGGCACG  | ATG CCG TCT CTG CTG GTG CTC ACT TTC TCC CCG TGC GTA |            |            |            |            |
|   |            | MET Pro Ser Leu Leu Val Leu Thr Phe Ser Pro Cys Val |            |            |            |            |
| 414   | 429        | 444   | 459        |            |            |            |
| CTA CTC GGC TGG GCG TTG CTG GCC GGC GGC ACC GGT GGC GGT GGC GTT GGC GGC |            |   |            |            |            |            |
| Leu Leu Gly Trp Ala Leu Leu Ala Gly Gly Thr Gly Gly Gly Gly Val Gly Gly |            |   |            |            |            |            |
| 474   | 489        | 504   |            |            |            |            |
| GGC GGC GGT GGC GCG ATA GGC GGC GGA CGC CAG GAG AGA GAG GCC GTG CCG     |            |   |            |            |            |            |
| Gly Gly Gly Gly Ala Gly Ile Gly Gly Gly Arg Gln Glu Arg Glu Ala Val Pro |            |   |            |            |            |            |
| 519   | 534        | 549   | 564        |            |            |            |
| CCA CAG AAG ATC GAG GTG CTG GTG TTA CTG CCC CAG GAT GAC TCG TAC TTG TTT |            |   |            |            |            |            |
| Pro Gln Lys Ile Glu Val Leu Val Leu Leu Pro Gln Asp Asp Ser Tyr Leu Phe |            |   |            |            |            |            |
| 579   | 594        | 609   | 624        |            |            |            |
| TCA CTC ACC CGG GTG CGG CCG GCC ATC GAG TAT GCT CTG CGC AGC GTG GAG GGC |            |   |            |            |            |            |
| Ser Leu Thr Arg Val Arg Pro Ala Ile Glu Tyr Ala Leu Arg Ser Val Glu Gly |            |   |            |            |            |            |
| 639   | 654        | 669   |            |            |            |            |
| AAC GGC ACT GGC AGG CGG CTT CTG CCG CCG GGC ACT CGC TTC CAG GTG GCT TAC |            |   |            |            |            |            |
| Asn Gly Thr Gly Arg Arg Leu Leu Pro Pro Gly Thr Arg Phe Gln Val Ala Tyr |            |   |            |            |            |            |
| 684   | 699        | 714   | 729        |            |            |            |
| GAG GAT TCA GAC TGT GGG AAC CGT GCG CTC TTC AGC TTG GTG GAC CGC GTG GCG |            |   |            |            |            |            |
| Glu Asp Ser Asp Cys Gly Asn Arg Ala Leu Phe Ser Leu Val Asp Arg Val Ala |            |   |            |            |            |            |
| 744   | 759        | 774   |            |            |            |            |
| GCG GCG CGG GGC GCC AAG CCA GAC CTT ATC CTG GGG CCA GTG TGC GAG TAT GCA |            |   |            |            |            |            |
| Ala Ala Arg Gly Ala Lys Pro Asp Leu Ile Leu Gly Pro Val Cys Glu Tyr Ala |            |   |            |            |            |            |

SUBSTITUTE SHEET

8/9

FIG. 5-2

|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|------|------|------|------|------|------|------|------|-----|------|------|------|------|------|-----|-----|------|-----|-----|--|
| 789  |      |      |      |      | 804  |      |      |     |      | 819  |      |      |      |     | 834 |      |     |     |  |
| GCA  | GCG  | CCA  | GTG  | GCC  | CGG  | CTT  | GCA  | TCG | CAC  | TGG  | GAC  | CTG  | CCC  | ATG | CTG | TCG  | GCT |     |  |
| Ala  | Ala  | Pro  | Val  | Ala  | Arg  | Leu  | Ala  | Ser | His  | Trp  | Asp  | Leu  | Pro  | MET | Leu | Ser  | Ala |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      | 849  |      |      |      |      |      | 864 |      |      |      |      | 879  |     |     |      |     | 894 |  |
| GGG  | GCG  | CTG  | GCC  | GCT  | GGC  | TTC  | CAG  | CAC | AAG  | GAC  | TCT  | GAG  | TAC  | TCG | CAC | CTC  | GAG |     |  |
| Gly  | Ala  | Leu  | Ala  | Ala  | Gly  | Phe  | Gln  | His | Lys  | Asp  | Ser  | Glu  | Tyr  | Ser | His | Leu  | Glu |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      |      |      | 909  |      |      |      |     | 924  |      |      |      |      | 939 |     |      |     |     |  |
| CGC  | GTG  | GCG  | CCC  | GCC  | TAC  | GCC  | AAG  | ATG | GGC  | GAG  | ATG  | ATG  | CTC  | GCC | CTG | TTC  | CGC |     |  |
| Arg  | Val  | Ala  | Pro  | Ala  | Tyr  | Ala  | Lys  | MET | Gly  | Glu  | MET  | MET  | Leu  | Ala | Leu | Phe  | Arg |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      | 954  |      |      |      |      | 969  |      |     |      | 984  |      |      |      |     |     | 999  |     |     |  |
| CAC  | CAC  | CAC  | TGG  | AGC  | CGC  | GCT  | GCA  | CTG | GTC  | TAC  | AGC  | GAC  | GAC  | AAG | CTG | GAG  | CGG |     |  |
| His  | His  | His  | Trp  | Ser  | Arg  | Ala  | Ala  | Leu | Val  | Tyr  | Ser  | Asp  | Asp  | Lys | Leu | Glu  | Arg |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      | 1014 |      |      |      |      | 1029 |     |      |      |      | 1044 |      |     |     |      |     |     |  |
| AAC  | TGC  | TAC  | TTC  | ACC  | CTC  | GAG  | GGG  | GTC | CAC  | GAG  | GTC  | TCC  | CAG  | GAG | GAG | GGT  | TTG |     |  |
| Asn  | Cys  | Tyr  | Phe  | Thr  | Leu  | Glu  | Gly  | Val | His  | Glu  | Val  | Ser  | Gln  | Glu | Glu | Gly  | Leu |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
| 1059 |      |      |      |      | 1074 |      |      |     | 1089 |      |      |      | 1104 |     |     |      |     |     |  |
| CAC  | ACG  | TCC  | ATC  | TAC  | AGT  | TTC  | GAC  | GAG | ACC  | AAA  | GAC  | TTG  | GAT  | CTG | GAA | GAC  | ATC |     |  |
| His  | Thr  | Ser  | Ile  | Tyr  | Ser  | Phe  | Asp  | Glu | Thr  | Lys  | Asp  | Leu  | Asp  | Leu | Glu | Asp  | Ile |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      | 1119 |      |      |      | 1134 |      |     |      | 1149 |      |      |      |     |     | 1164 |     |     |  |
| CTG  | CGC  | AAT  | ATC  | CAG  | GCC  | AGT  | GAG  | AGA | GTG  | GTG  | ATC  | ATG  | TGT  | GCG | AGC | AGT  | GAC |     |  |
| Leu  | Arg  | Asn  | Ile  | Gln  | Ala  | Ser  | Glu  | Arg | Val  | Val  | Ile  | MET  | Cys  | Ala | Ser | Ser  | Asp |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      |      | 1179 |      |      |      | 1194 |     |      |      |      | 1209 |      |     |     |      |     |     |  |
| ACC  | ATC  | CGG  | AGC  | ATC  | ATG  | CTG  | GTG  | GCG | CAC  | AGG  | CAT  | GGC  | ATG  | ACC | AGT | GGA  | GAC |     |  |
| Thr  | Ile  | Arg  | Ser  | Ile  | MET  | Leu  | Val  | Ala | His  | Arg  | His  | Gly  | MET  | Thr | Ser | Gly  | Asp |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      | 1224 |      |      |      | 1239 |      |      |     | 1254 |      |      |      | 1269 |     |     |      |     |     |  |
| TAC  | GCC  | TTC  | TTC  | AAC  | ATT  | GAG  | CTC  | TTC | AAC  | AGC  | TCT  | TCC  | TAT  | GGA | GAT | GGC  | TCA |     |  |
| Tyr  | Ala  | Phe  | Phe  | Asn  | Ile  | Glu  | Leu  | Phe | Asn  | Ser  | Ser  | Ser  | Tyr  | Gly | Asp | Gly  | Ser |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      | 1284 |      |      |      | 1299 |      |     | 1314 |      |      |      |      |     |     |      |     |     |  |
| TGG  | AAG  | AGA  | GGA  | GAC  | AAA  | CAC  | GAC  | TTT | GAA  | GCT  | AAG  | CAA  | GCA  | TAC | TCG | TCC  | CTC |     |  |
| Trp  | Lys  | Arg  | Gly  | Asp  | Lys  | His  | Asp  | Phe | Glu  | Ala  | Lys  | Gln  | Ala  | Tyr | Ser | Ser  | Leu |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
| 1329 |      |      |      | 1344 |      |      | 1359 |     |      |      | 1374 |      |      |     |     |      |     |     |  |
| CAG  | ACA  | GTC  | ACT  | CTA  | CTG  | AGG  | ACA  | GTG | AAA  | CCT  | GAG  | TTT  | GAG  | AAG | TTT | TCC  | ATG |     |  |
| Gln  | Thr  | Val  | Thr  | Leu  | Leu  | Arg  | Thr  | Val | Lys  | Pro  | Glu  | Phe  | Glu  | Lys | Phe | Ser  | MET |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      | 1389 |      |      |      | 1404 |      |      |     | 1419 |      |      |      |      |     |     | 1434 |     |     |  |
| GAG  | GTG  | AAA  | AGT  | TCA  | GTT  | GAG  | AAA  | CAA | GGG  | CTC  | AAT  | ATG  | GAG  | GAT | TAC | GTT  | AAC |     |  |
| Glu  | Val  | Lys  | Ser  | Ser  | Val  | Glu  | Lys  | Gln | Gly  | Leu  | Asn  | MET  | Glu  | Asp | Tyr | Val  | Asn |     |  |
|      |      |      |      |      |      |      |      |     |      |      |      |      |      |     |     |      |     |     |  |
|      |      | 1449 |      |      |      | 1464 |      |     | 1479 |      |      |      |      |     |     |      |     |     |  |
| ATG  | TTT  | GTT  | GAA  | GGA  | TTC  | CAC  | GAT  | GCC | ATC  | CTC  | CTC  | TAC  | GTC  | TTG | GCT | CTA  | CAT |     |  |
| MET  | Phe  | Val  | Glu  | Gly  | Phe  | His  | Asp  | Ala | Ile  | Leu  | Leu  | Tyr  | Val  | Leu | Ala | Leu  | His |     |  |

SUBSTITUTE SHEET

9/9

## FIG. 5-3

```

1494      1509      1524      1539
GAA GTA CTC AGA GCT GGT TAC AGC AAA AAG GAT GGA GGG AAA ATT ATA CAG CAG
Glu Val Leu Arg Ala Gly Tyr Ser Lys Lys Asp Gly Gly Lys Ile Ile Gln Gln

      1554      1569      1584
ACT TGG AAC AGA ACA TTT GAA GGT ATC GCC GGG CAG GTG TCC ATA GAT GCC AAC
Thr Trp Asn Arg Thr Phe Glu Gly Ile Ala Gly Gln Val Ser Ile Asp Ala Asn

1599      1614      1629      1644
GGA GAC CGA TAT GGG GAT TTC TCT GTG ATT GCC ATG ACT GAT GTG GAG GCG GGC
Gly Asp Arg Tyr Gly Asp Phe Ser Val Ile Ala MET Thr Asp Val Glu Ala Gly

      1659      1674      1689      1704
ACC CAG GAG GTT ATT GGT GAT TAT TTT GGA AAA GAA GGT CGT TTT GAA ATG CCG
Thr Gln Glu Val Ile Gly Asp Tyr Phe Gly Lys Glu Gly Arg Phe Glu MET Arg

      1719      1734      1749
CCG AAT GTC AAA TAT CCT TGG GGC CCT TTA AAA CTG AGA ATA GAT GAA AAC CGA
Pro Asn Val Lys Tyr Pro Trp Gly Pro Leu Lys Leu Arg Ile Asp Glu Asn Arg

      1764      1779      1794      1809
ATT GTA GAG CAT ACA AAC AGC TCT CCC TGC AAA TCA TCA GGT GGC CTA GAA GAA
Ile Val Glu His Thr Asn Ser Ser Pro Cys Lys Ser Ser Gly Gly Leu Glu Glu

      1824      1839      1854
TCG GCA GTG ACA GGA ATT GTC GTG GGG GCT TTA CTA GGA GCT GGC TTG CTA ATG
Ser Ala Val Thr Gly Ile Val Val Gly Ala Leu Leu Gly Ala Gly Leu Leu MET

1869      1884      1899      1914
GCC TTC TAC TTT TTC AGG AAG AAA TAC AGA ATA ACC ATT GAG AGG CGA ACC CAG
Ala Phe Tyr Phe Phe Arg Lys Lys Tyr Arg Ile Thr Ile Glu Arg Arg Thr Gln

      1929      1944      1959      1974
CAA GAA GAA AGT AAC CTT GGA AAA CAT CGG GAA TTA CGG GAA GAT TCC ATC AGA
Gln Glu Glu Ser Asn Leu Gly Lys His Arg Glu Leu Arg Glu Asp Ser Ile Arg

      1989      2002      2012      2022      2032      2042
TCC CAT TTT TCA GTA GCT TAAAGGAAGC CCCCCACTTT TTTTTTTTCT GCCTGAGATT CTTTAAGGAG
Ser His Phe Ser Val Ala

      2052      2062      2072      2082      2092
ATAGACGGGT TGAAAGACAT CAATGAAACA GAAGGGGCGT TCTTGAAGAA TTC

```

TRANSLATE [Partial]: q

SEQ: q

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US87/01122

|  |   |                                     |
|--|---|-------------------------------------|
| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>3</sup>  |   |                                     |
| According to International Patent Classification (IPC) or to both National Classification and IPC<br>IPC(4) C07K 3/02, 3/20, 13/00, 15/00; A61K 37/00; C12Q 1/68, C12P 21/00, 21/02; C12N15/00, 1/20, 1/00; C07H 21/04   |   |                                     |
| <b>II. FIELDS SEARCHED</b>   |   |                                     |
| Minimum Documentation Searched <sup>4</sup>  |   |                                     |
| Classification System  | Classification Symbols  |                                     |
| U.S.   | 530/350, 413; 514/12, 21; 435/6, 68, 70, 172.3, 240, 253, 317; 536/27; 935/9, 11  |                                     |
| Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>4</sup>   |   |                                     |
| COMPUTER SEARCH, CAS, APS: ATRIOPEPTIN OR CARDIONATRIN OR ATRIA NATRIURETIC RECEPTOR   |   |                                     |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>  |   |                                     |
| Category <sup>5</sup>  | Citation of Document, <sup>10</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>  | Relevant to Claim No. <sup>18</sup> |
| Y  | Biochemical And Biophysical Research Communications Vol. 130, issued 31 July, 1985 (New York, USA), (HIROSE ET AL), "Solubilization and Molecular Weight Estimation of Atrial Natriuretic Factor Receptor From Bovine Adrenal Cortex", pages 574-579. | 1-20                                |
| Y  | Biochemical And Biophysical Research Communications Vol. 132, issued 30 Oct., 1985 (New York, USA), (CARRIER ET AL), "Partial Characterization and Solubilization of Receptors For Atrial Natriuretic Factor In Rat Glomeruli", pages 666-673.        | 1-20                                |
| Y  | The Journal Of Biological Chemistry Vol. 261, issued 5 May, 1986 (Baltimore Maryland USA), (KUNO ET AL), "Co-purification of an Atrial Natriuretic Factor Receptor and Particulate Guanylate Cyclase from Rat Lung," pages 5817-5823.                 | 1-20                                |
| <p><sup>15</sup> Special categories of cited documents: <sup>16</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> |   |                                     |
| <b>IV. CERTIFICATION</b>   |   |                                     |
| Date of the Actual Completion of the International Search <sup>1</sup>   | Date of Mailing of this International Search Report <sup>1</sup>  |                                     |
| 16 JUNE 1987   | 02 JUL 1987   |                                     |
| International Searching Authority <sup>1</sup>   | Signature of Authorized Officer <sup>20</sup>   |                                     |
| ISA/US   | Alvin E. Tanenholtz   |                                     |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) |  |                                    |
|--|--|------------------------------------|
| Category <sup>16</sup>   | Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>   | Relevant to Claim No <sup>18</sup> |
| Y  | <u>The Journal Of Biological Chemistry</u> Vol. 260, issued 5 September, 1985, (Baltimore Maryland, USA), (WIMALASENA ET AL), "The Porcine LH/hCG Receptor", pages 10689-10697.  | 1-20                               |
| Y  | <u>Proc. Natl. Acad. Sci. USA</u> Vol. 81, issued May 1984, (Washington, D.C.), (SEIDAH ET AL), "Amino acid sequence of homologous rat atrial peptides: Natriuretic activity of native and synthetic forms," pages 2640-2644.                                | 1-20                               |
| Y  | <u>Nature</u> Vol. 309 issued June 1984, (London, England), (YAMANAKA ET AL), "Cloning and sequence analysis of the cDNA for rat atrial natriuretic factor precursor," pages 719-722, see particular page 720.   | 1-20                               |
| Y  | <u>Nature</u> Vol. 309, issued 21 June, 1984 (London, England), (ATLAS ET AL), "Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide", pages 717-719, especially Fig. 1.  | 1-20                               |
| Y  | <u>Nature</u> Vol. 312, issued 20/27 December, 1984 (London England), (COSMAN ET AL), "Cloning, sequence and expression of human interleukin-2 receptor," pages 768-771.   | 1-20                               |
| Y  | US, A, 4,562,003 (LEWICKI) published December 31 1985.   | 18-20                              |
| Y  | <u>The Journal Of Immunology</u> Vol. 126, issued April 1981 (Baltimore Maryland, USA), (UCHIYAMA ET AL), "A Monoclonal Antibody (Anti-Tac) Reactive With Activated And Functionally Mature Human T-Cells", pages 1393-1397, especially pages 1393 and 1394. | 18-20                              |

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

Proc. Natl. Acad. Sci. USA Vol. 81, issued October 1984, (Washington, D.C.), (URDAL ET AL), "Purification and chemical characterization of the receptor for interleukin 2 from activated human T lymphocytes and from a human T-cell lymphoma cell line", pages 6481-6485, especially pages 6482 and 6483.

1-20

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>10</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..... because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:

2. ☐ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>11</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.